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The physicochemical and mechanical properties and the 
mechanisms of drug release from drug delivery systems prepared by hot-
melt extrusion were investigated.  The influence of processing conditions 
and the thermal properties of the polymeric retardants was also studied. 
The stability of polyethylene oxide (PEO) in sustained release 
tablets prepared by hot-melt extrusion was investigated.  The chemical 
stability of PEO was found to be dependent on the storage and processing 
temperature, the screw speed and the molecular weight of the polymer.  
Lower molecular weight PEO MW = 100,000 (PEO 100K) was 
demonstrated to be a suitable processing aid for PEO 1M.  Vitamin E, 
Vitamin E Succinate and Vitamin E TPGS were found to be suitable 
stabilizers for PEO; however, ascorbic acid was shown to degrade the 
polymer in solution.  Drug release rates from hot-melt extruded tablets 
 ix 
stabilized with antioxidants were found to be dependent on the hydrophilic 
nature of the antioxidant.  The physicochemical properties and mechanism 
of drug release from ethyl cellulose matrix tablets containing a water 
soluble drug (guaifenesin) were investigated.  Tablets were prepared by 
direct compression and hot-melt extrusion techniques.  The drug 
dissolution and release kinetics were determined and the tablet pore 
characteristics, tortuosity, thermal properties and surface morphologies 
were studied.  The tortuosity was measured directly by a novel technique 
that allows for the calculation of diffusion coefficients in 3 experiments.  
The Higuchi diffusion model, percolation theory and polymer free volume 
theory were applied to the dissolution data to explain the release 
properties of drug from the matrix systems. Films containing PEO and two 
model drugs (guaifenesin and ketoprofen) were prepared by hot-melt 
extrusion.  Both guaifenesin and ketoprofen were stable during the 
extrusion process.  Wide angle X-ray diffraction suggested that 
guaifenesin crystallized from the melt upon cooling, but ketoprofen 
formed a solid solution.  Crystallization of guaifenesin on the surface of 
the film could be observed using scanning electron microscopy at all 
concentrations studies, but did not reveal ketoprofen crystallization until 
reaching the 15% level.  Guaifenesin and ketoprofen were found to 
 x 
decrease the drive load, increase the stability of polyethylene oxide and 
plasticize the polymer during extrusion.  The percent elongation decreased 
with increasing guaifenesin concentrations, but increased with increasing 
ketoprofen concentrations.  Both guaifenesin and ketoprofen decreased 
the tensile strength of the film. 
  
 xi 
TABLE OF CONTENTS 
LIST OF TABLES XVII 
LIST OF FIGURES XIX 
CHAPTER 1  INTRODUCTION 1 
1.1  Pharmaceutical Applications of Hot-Melt Extrusion 1 
1.2  Equipment, Principles of Extrusion and Process Technology 5 
1.2.1  Hot-Melt Extrusion Equipment 5 
1.2.2  The Hot-Melt Extrusion Process 15 
1.2.3  Wet Extrusion versus Dry Extrusion 17 
1.2.4  Mass Flow during Hot-Melt Extrusion 18 
1.3  Materials used in Hot-Melt Extrusion 20 
1.3.1  Carriers 21 
1.3.2  Plasticizers 27 
1.3.3  Other Processing Aids 31 
1.3.4  Drugs 34 
1.4  Properties of Hot-melt Extruded Dosage Forms 38 
1.4.1  Chemical Stability of Drug Substances during Hot-Melt 
Extrusion 38 
1.4.2  Thermal and Crystalline Properties of Hot-Melt Extruded 
Dosage Forms 39 
1.5  Hot-Melt Extruded Dosage Forms 45 
1.5.1  Granules, Pellets & Spheres 45 
1.5.2  Tablets 52 
 xii 
1.5.3  Transdermal and Transmucosal Films 56 
1.5.4  Implants 60 
1.6  Quality Control and Regulatory Considerations 63 
1.7  A View to the Future 63 
CHAPTER 2  RESEARCH OBJECTIVES 65 
2.1  Overall Objectives 65 
2.2  Supporting Objectives 65 
2.2.1  Investigate the Stability of Polyethylene Oxide in Matrix 
Tablets Prepared by Hot-Melt Extrusion 65 
2.2.2  Characterize the Physicochemical Properties and 
Mechanism of Drug Release from Ethyl Cellulose Matrix 
Tablets prepared by Direct Compression and Hot-melt 
Extrusion 67 
2.2.3  Investigate the Influence of Guaifenesin and 
Ketoprofen on the Mechanical Properties of Hot-melt 
Extruded Polyethylene Oxide Films 68 
CHAPTER 3  AN INVESTIGATION OF THE STABILITY OF POLYETHYLENE 
OXIDE IN MATRIX TABLETS PREPARED BY HOT-MELT EXTRUSION 70 
3.1 Abstract 70 
3.2 Introduction 71 
3.3  Materials and Methods 74 
3.3.1  Materials 74 
3.3.2  Thermogravimetric Analysis 74 
3.3.3  Molecular Weight Determination 75 
3.3.4  Differential Scanning Calorimetry Analysis 76 
 xiii 
3.3.5  Hot-melt Extrusion Process 76 
3.3.6  In Vitro Release Properties 77 
3.4  Results and Discussion 78 
3.4.1  The Thermal Stability of PEO 78 
3.4.2  The Hot-melt extrusion stability of PEO 85 
3.4.3  The Influence of Low Molecular Weight PEO 90 
3.4.4  The Influence of Antioxidants 94 
3.5  Conclusions 103 
3.6  Acknowledgements 104 
CHAPTER 4  CHARACTERIZATION OF THE PHYSICOCHEMICAL 
PROPERTIES AND MECHANISM OF DRUG RELEASE FROM ETHYL 
CELLULOSE MATRIX TABLETS PREPARED BY DIRECT COMPRESSION AND 
HOT-MELT EXTRUSION 105 
4.1  Abstract 105 
4.2  Introduction 106 
4.3  The Theory of Mercury Intrusion Porosimetry and Tortuosity 109 
4.4  Materials and Methods 113 
4.4.1  Materials 113 
4.4.2  Methods 113 
4.4.2.1  Preparation of Tablets 113 
4.4.2.2  Direct Compression Process 114 
4.4.2.3  Hot-Melt Extrusion Process 114 
4.4.2.4  In Vitro Release Properties 115 
4.4.2.5  True Density by Helium Pycnometry 116 
4.4.2.6  Mercury Intrusion Porosimetry 116 
 xiv 
4.4.2.7  Percent Effective Porosity Determination 117 
4.4.2.8  Modulated Differential Scanning Calorimetry 
Analysis 118 
4.4.2.9  Scanning Electron Microscopy 118 
4.4.2.10  Statistical Analysis 119 
4.5  Results & Discussion 119 
4.5.1  The Influence of Ethyl Cellulose Particle Size on Drug 
Release 119 
4.5.2  The Influence of Tableting Technique on Drug Release 128 
4.5.3  The Influence of Compaction Force on Drug Release 132 
4.5.4  The Influence of Hot-Melt Extrusion Temperature on 
Drug Release 132 
4.5.5  Pore Characteristics Prior to & After Dissolution Testing 140 
4.5.6  Determination of Drug Release Kinetics 144 
4.6  Conclusions 149 
4.7  Acknowledgements 150 
CHAPTER 5  THE INFLUENCE OF GUAIFENESIN AND KETOPROFEN ON THE 
PROPERTIES OF HOT-MELT EXTRUDED POLYETHYLENE OXIDE FILMS 151 
5.1 Abstract 151 
5.2  Introduction 152 
5.3  Materials and Methods 155 
5.3.1  Materials 155 
5.3.2  Methods 155 
5.3.2.1  Hot-Melt Extrusion 155 
5.3.2.2  Drug Content 156 
 xv 
5.3.2.3  Wide Angle X-Ray Diffraction 157 
5.3.2.4  Differential Scanning Calorimetry 158 
5.3.2.5  Scanning Electron Microscopy 158 
5.3.2.6  Gel Permeation Chromatography 159 
5.3.2.7  Mechanical Testing 160 
5.3.2.7  Statistical Analysis 161 
5.4  Results & Discussion 161 
5.4.1  Physicochemical Characterization of Hot-melt Extruded 
PEO Films and Films containing Guaifenesin and 
Ketoprofen 161 
5.4.2  Calculated Solubility Parameters of Guaifenesin, 
Ketoprofen and Polyethylene Oxide and their 
Relationship to the Experimental Results. 181 
5.4.3  The Influence of Guaifenesin and Ketoprofen on the 
Mechanical Properties of Hot-melt Extruded 
Polyethylene Oxide Films 184 
5.5  Conclusions 193 
5.6  Acknowledgements 194 
CHAPTER 6  SUMMARY AND CONCLUSIONS 195 
6.1  Summary of Results 195 
6.2  Stability of Polyethylene Oxide in Matrix Tablets Prepared By 
Hot-Melt Extrusion 195 
6.3  Physicochemical Properties and Mechanism of Drug Release 
from Ethyl Cellulose Matrix Tablets prepared by Direct 
Compression and Hot-melt Extrusion 197 
 xvi 
6.4  The Influence of Guaifenesin and Ketoprofen on the 
Properties of Hot-melt Extruded Polyethylene Oxide Films 198 
BIBLIOGRAPHY                       200 
VITA 239 
 
 
 xvii 
List of Tables 
  
Table 1.2 Common plasticizers used in pharmaceutical dosage 
forms .................................................................................................30 
Table 1.3  Common processing aids used in hot-melt extruded 
dosage forms......................................................................................33 
Table 1.4  Drug Substances processed by hot-melt extrusion 
techniques..........................................................................................36 
Table 1.5:  Common Methods used for the characterization of hot-
melt extrudates...................................................................................44 
Table 3.1:  Extrusion Stability of PEO 1M and the Influence of PEO 
100K on PEO Weight Average Molecular Weight as measured by 
Gel Permeation Chromatography..........................................................92 
Table 3.2:  Extrusion Stability of PEO 1M and the Influence of 
Antioxidants on PEO Weight Average Molecular Weight as 
measured by Gel Permeation Chromatography......................................95 
Table 3.3:  Influence of Ascorbic Acid on the Solution Stability of 
Polyethylene Oxide 1M as measured by Gel Permeation 
Chromatography...............................................................................100 
Table 4.1:  Median pore radius, % porosity and tortuosity of 
matrix tablets prepared by direct compression (DC) and hot-melt 
extrusion (HME) containing 30% guaifenesin and 70% ethyl 
cellulose measured before and after dissolution testing. ......................126 
 xviii 
Table 4.2:  Kinetic data from regression fitting to Higuchi Diffusion 
Model giving the rate constant k (g/cm2s1/2), the y-intercept 
(g/cm2), the correlation coefficient r2, the apparent diffusion 
coefficient Dapp (cm2/s) and the diffusion coefficient Ds from the 
plot of drug release (g/cm2) against the square root of time (s1/2)........148 
Table 5.1:  Stability of PEO in Hot- Melt Extruded Films containing 
either Guaifenesin or Ketoprofen as Determined by Gel Permeation 
Chromatography...............................................................................180 
Table 5.2:  Calculated Interaction Parameters and Solubility 
Parameters for Guaifenesin, Ketoprofen and Polyethylene Oxide..........183 
 
 xix 
List of Figures 
  
Figure 1.1:  The number of hot-melt extrusion patents issued for 
pharmaceutical applications from 1983 to 2002. .....................................3 
Figure 1.2:  The number and percentage of hot-melt extrusion 
patents issued since 1983 for pharmaceutical applications by 
country.................................................................................................4 
Figure 1.3:  Schematic diagram of a single screw extruder. ...................7 
Figure 1.4:  Diagram of an extruder screw............................................9 
Figure 1.5:  Illustration of dies and resultant extrudate shapes. ...........12 
Figure 1.6:  Illustration of a pelletizer used to chop rod shaped 
extrudates into pellets or granules. ......................................................13 
Figure 1.7:  Illustration of a hot-melt extrusion film assembly with 
chill rolls and torque winder.................................................................14 
Figure 3.1:  Influence of storage temperature on the weight 
average molecular weight of Polyethylene Oxide (PEO Mw = 
1,000,000)..........................................................................................80 
Figure 3.2:  Relationship of polymer molecular weight in the 
thermal stability of Polyethylene Oxide when stored at 60°C, 75% 
relative humidity.................................................................................82 
Figure 3.3:  DSC profiles of the CPM, PEO and Antioxidants.................84 
 xx 
Figure 3.4:  Influence of extrusion temperature & screw speed on 
the weight average molecular weight of PEO 1M (80% PEO 1M, 
20% CPM)..........................................................................................87 
Figure 3.5:  Influence of processing temperature & screw speed 
on drive amperage..............................................................................89 
Figure 3.6:  Influence of low molecular weight PEO on CPM 
release from hot-melt extruded tablets using USP Method II at 37°C 
and 100 rpm in 900 ml purified water...................................................93 
Figure 3.7:  DSC profiles of the Physical Mixtures and Extruded 
Tablets...............................................................................................97 
Figure 3.8:  Influence of antioxidants on the release of CPM from 
tablets using USP Method II at 37°C and 100 rpm in 900 ml 
purified water. ..................................................................................102 
Figure 4.1:  Influence of ethyl cellulose particle size, compaction 
force and extrusion temperature on guaifenesin release from matrix 
tablets prepared by direct compression and hot-melt extrusion............121 
Figure 4.2:  Influence of ethyl cellulose particle size, compaction 
force and extrusion temperature on guaifenesin release from matrix 
tablets prepared by direct compression and hot-melt extrusion............122 
Figure 4.3:  3-Dimensional image of the molecular dimensions of 
Guaifenesin using SAVOL3 software...................................................125 
Figure 4.4:  Modulated differential scanning calorimetry profiles of 
ethyl cellulose, guaifenesin, physical mixtures and hot-melt 
extrudates. .......................................................................................131 
 xxi 
Figure 4.5:  SEM micrographs of the surface of hot-melt extruded 
matrix tablets containing 30% guaifenesin and 70% “Fine” ethyl 
cellulose processed at 80, 85, 85, 90°C viewed at 1,000 X 
magnification....................................................................................135 
Figure 4.6:  SEM micrographs of the surface of hot-melt extruded 
matrix tablets containing 30% guaifenesin and 70% “Fine” ethyl 
cellulose processed at 90, 105, 105, 110°C viewed at 1,000 X 
magnification....................................................................................136 
Figure 4.7:  SEM micrographs of the surface of hot-melt extruded 
matrix tablets containing 30% guaifenesin and 70% “Coarse” ethyl 
cellulose processed at 80, 85, 85, 90°C viewed at 1,000 X 
magnification....................................................................................137 
Figure 4.8:  SEM micrographs of the surface of hot-melt extruded 
matrix tablets containing 30% guaifenesin and 70% “Coarse” ethyl 
cellulose processed at 90, 105, 105, 110°C viewed at 1,000 X 
magnification....................................................................................138 
Figure 4.9:  SEM micrographs of the surface of hot-melt extruded 
matrix tablets containing 30% guaifenesin and 70% “Coarse” ethyl 
cellulose processed at 90, 105, 105, 110°C viewed at 10,000 X 
magnification....................................................................................139 
Figure 4.10:  SEM micrographs at 1,000X magnification of the 
surface of hot-melt extruded matrix tablets containing 30% 
guaifenesin and 70% “Coarse” ethyl cellulose processed at 90, 105, 
105, 110°C measured after 24 hour dissolution testing........................142 
 xxii 
Figure 4.11:  SEM micrographs at 10,000X magnification of the 
surface of hot-melt extruded matrix tablets containing 30% 
guaifenesin and 70% “Coarse” ethyl cellulose processed at 90, 105, 
105, 110°C measured after 24 hour dissolution testing........................143 
Figure 4.12:  Higuchi Diffusion model fitting of the guaifenesin 
release data from matrix tablets prepared by direct compression 
and hot-melt extrusion......................................................................146 
Figure 4.13:  Higuchi Diffusion model fitting of the guaifenesin 
release data from matrix tablets prepared by direct compression 
and hot-melt extrusion......................................................................147 
Figure 5.1: Wide angle X-Ray diffraction profiles of PEO powder, 
guaifenesin, hot-melt extruded PEO film, physical mixtures of PEO 
and guaifenesin and hot-melt extruded films of PEO and 
guaifenesin.......................................................................................164 
Figure 5.2:  Wide angle X-Ray diffraction profiles of PEO powder, 
ketoprofen, hot-melt extruded PEO film, physical mixtures of PEO 
and ketoprofen and hot-melt extruded films of PEO and ketoprofen.....165 
Figure 5.3:  Differential Scanning Calorimetry profiles of PEO, 
guaifenesin, a physical mixture of GFN and PEO, and GFN loaded 
films.................................................................................................168 
Figure 5.4:  Differential Scanning Calorimetry profiles of PEO, 
ketoprofen, a physical mixture of KTP and PEO, and KTP loaded 
films.................................................................................................170 
 xxiii 
Figure 5.5:  SEM micrograph of the surface morphology of hot-
melt extruded PEO film at 100 x magnification....................................171 
Figure 5.6:  SEM micrograph of the surface morphology of hot-
melt extruded film containing 95% PEO and 5% GFN at 100 x 
magnification....................................................................................172 
Figure 5.7:  SEM micrograph of the surface morphology of hot-
melt extruded film containing 90% PEO and 10% GFN at 100 x 
magnification....................................................................................173 
Figure 5.8:  SEM micrograph of the surface morphology of hot-
melt extruded film containing 85% PEO and 15% GFN at 100 x 
magnification....................................................................................174 
Figure 5.9:  SEM micrograph of the surface morphology of hot-
melt extruded film containing 70% PEO and 30% GFN at 100 x 
magnification....................................................................................175 
Figure 5.10:  SEM micrograph of the surface morphology of hot-
melt extruded film containing 95% PEO and 5% KTP at 100 x 
magnification....................................................................................176 
Figure 5.11:  SEM micrograph of the surface morphology of hot-
melt extruded film containing 90% PEO and 10% KTP at 100 x 
magnification....................................................................................177 
Figure 5.12:  SEM micrograph of the surface morphology of hot-
melt extruded film containing 85% PEO and 15% KTP at 100 x 
magnification....................................................................................178 
 xxiv 
Figure 5.13:  The percent elongation of hot-melt extruded 
polyethylene oxide (PEO) films and films containing various 
concentrations of guaifenesin (GFN) or ketoprofen (KTP), n= 6. ..........186 
Figure 5.14:  The tensile strength of hot-melt extruded 
polyethylene oxide (PEO) films and films containing various 
concentrations of guaifenesin (GFN) or ketoprofen (KTP), n=6. ...........187 
Figure 5.15:  SEM micrograph of the surface morphology of 
guaifenesin at 500 x magnification.....................................................191 
Figure 5.16:  SEM micrograph of the surface morphology of 
ketoprofen at 5990 x magnification....................................................192 
 
 
 
 1 
CHAPTER 1  INTRODUCTION 
 
1.1  PHARMACEUTICAL APPLICATIONS OF HOT-MELT EXTRUSION 
Hot-melt extrusion is a widely applied processing technique within 
the plastics industry.  Hot-melt extrusion is the process of pumping raw 
materials with a rotating screw under elevated temperature through a die 
into a product of uniform shape.  Currently, more than half of all plastic 
products, including plastic bags, sheets, and pipes, are manufactured by 
this process [1].  Hot melt extrusion was first introduced in the plastics 
industry in the mid-nineteenth century to prepare polymeric insulation 
coatings to wires.  Today, interest in hot-melt extrusion techniques for 
pharmaceutical applications is growing rapidly with over 100 papers 
published in the literature.  The number of hot-melt extrusion patents 
issued for pharmaceutical systems has steadily increased since the early 
1980’s (Figure 1.1) with international scope (Figure 1.2). 
Several research groups have demonstrated hot-melt extrusion 
processes as a viable method to prepare pharmaceutical drug delivery 
systems, including granules [2], pellets [3, 4], sustained release tablets 
[5-9], transdermal and transmucosal drug delivery systems [10-17] and 
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implants [18-21].  The hot-melt extrusion technique is an attractive 
alternative to traditional solvent casting methods.  
Hot-melt extrusion offers many advantages over traditional 
pharmaceutical processing techniques. Molten polymers during the 
extrusion process can function as thermal binders and act as drug depots 
and/or drug release retardants upon cooling and solidification.  Solvents 
and water are not necessary reducing the number of processing steps and 
eliminating time-consuming drying steps.  The active ingredients do not 
need to be compressible and the entire procedure is continuous and 
efficient.  The intense mixing and agitation imposed by the rotating screw 
cause de-aggregation of suspended particles in the molten polymer 
resulting in a more uniform dispersion.  Hot-melt extrusion has been used 
to improve the bioavailability of drug substances by formation of 
molecular dispersions.  Hot-melt extrusion requires a pharmaceutical 
grade polymer that can be processed at relatively low temperatures due 
to the thermal sensitivity of many drugs.  All components must be 
thermally stable at the processing temperature during the short duration 
of the heating process. 
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Figure 1.1:  The number of hot-melt extrusion patents issued for 
pharmaceutical applications from 1983 to 2002. 
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Figure 1.2:  The number and percentage of hot-melt extrusion patents 
issued since 1983 for pharmaceutical applications by country. 
 5 
1.2  EQUIPMENT, PRINCIPLES OF EXTRUSION AND PROCESS 
TECHNOLOGY 
1.2.1  Hot-Melt Extrusion Equipment 
Extrusion processes can be categorized as ram extrusion or screw 
extrusion.  Screw extrusion consists of a rotating screw inside a heated 
barrel, while ram extrusion operates with a positive displacement ram 
capable of generating high pressures to push materials through the die.  
Materials are subjected to higher shear stress and more intense mixing in 
a screw extruder.  Extrudates prepared by screw extrusion are more 
homogeneous, in comparison with extrudates that are processed by ram 
extrusion.  Screw extruders include single screw and twin screw extruders.  
In a twin screw extruder, two screws can either rotate in the same (co-
rotating extruder) or the opposite (counter-rotating extruder) direction.   
The first twin screw extruders were developed in the late 1930’s in Italy.  
Twin screw extruders have several advantages over single screw 
extruders, such as easier material feeding, high kneading and dispersing 
capacities, less tendency to over heat and shorter transit time.   
During ram extrusion, materials are introduced into a heated 
cylinder.  After an induction period to soften the materials, a ram (or a 
 6 
piston) pressurizes the soft materials through the die and transforms them 
into the desired shape.  High-pressure is the operating principle of the 
ram extrusion.  The major drawback of ram extrusion is limited melting 
capacity which causes poor temperature uniformity in the extrudate.  
An extruder consists of three distinct parts: a conveying system for 
material transport and mixing, a die system for forming and downstream 
auxiliary equipment for cooling, cutting or collecting the finished goods.  
Individual components within the extruder are the feed hopper, barrel, 
screw, die, screw driving motor and heating and cooling systems (Figure 
1.3).  Standard process control and monitoring devices include 
temperature and screw speed with optional monitoring of torque, drive 
amperage, pressure and melt viscosity.  Temperatures are normally 
controlled by electrical heating bands, and the temperature is monitored 
by thermocouples.  
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Figure 1.3:  Schematic diagram of a single screw extruder. 
 
(From Reference [22]) 
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Most commercial extruders have a modular design to facilitate 
changing screws.  The design of the screw has a significant impact on the 
process and can be selected to meet particular requirements such as high 
or low shear.  Whelan and Dunning have reviewed the various screw 
designs available [23].    Specific screw features are displayed in Figure 
1.4.  Screws are designed with several sections, with the function of each 
section ranging from feeding, mixing, compression, and metering.  Most 
screws are made from surface coated stainless steel to reduce friction and 
the possibility of chemical reactions.   
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Figure 1.4:  Diagram of an extruder screw. 
 
The channel depth is the distance from the screw roots to the inner barrel 
surface, the flight clearance is the distance between the screw flight and 
the inner barrel surface, the channel width is the distance between two 
neighboring flights, the helix angle is the angle between the flight and the 
direction perpendicular to the screw axis. 
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The screw is typically divided into three sections along the length of 
the barrel: feeding, melting or compression, and metering as shown in 
Figure 1.3.  The purpose of the feeding section is to transfer the materials 
from the hopper to the barrel.  The channel depth is usually widest in this 
section to facilitate mass flow.  A decrease in channel depth in the 
compression zone increases the pressure which removes entrapped air.  
The polymer typically begins to soften and melt in the compression zone.  
Thermoplastic polymers primarily exist in a molten state when entering 
the metering section.  The mass flow rate of the extrudate is highly 
dependent upon the channel depth and the length of the metering 
section.   
The die is attached at the end of the barrel.  The shape of the die 
controls the form of the extrudate (Figure 1.5).  Generally, the cross 
section of the extrudate will increase upon leaving the die, a phenomenon 
known as “die swell” due to the viscoelastic properties of polymers.  This 
entropy driven event occurs as the individual polymer chains recover from 
the deformation imposed by the rotating screw by “relaxing” and 
increasing their radius of gyration. 
Several types of downstream equipment are necessary to further 
process the extrudate into its desired form.  Pelletizers are used to chop 
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small diameter rods into pellets or granules (Figure 1.6).  For film 
applications, chill rolls and torque winders are used to rapidly cool and 
collect the extrudate (Figure 1.7).  Film thickness can be adjusted by 
changing the rotation speed of the chill rolls or the torque winder. 
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Figure 1.5:  Illustration of dies and resultant extrudate shapes. 
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Figure 1.6:  Illustration of a pelletizer used to chop rod shaped 
extrudates into pellets or granules. 
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Figure 1.7:  Illustration of a hot-melt extrusion film assembly with chill 
rolls and torque winder. 
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1.2.2  The Hot-Melt Extrusion Process 
The different zones of the barrel are pre-set to specific 
temperatures before the extrusion process.  The feed stock is placed in 
the hopper and transferred into the heated barrel by the rotating screw.  
The feed stock must have good flow properties.  This requirement is 
usually met by insuring that the angle of the feed hopper exceeds the 
angle of repose of the feed materials.  When this prerequisite is not met, 
the feed stock tends to form a solid bridge at the throat of the hopper 
resulting in erratic flow.  In these situations, a force feeding device can be 
used. 
As the feed stock is moved along the length of the barrel, heat is 
generated by shearing imposed by the rotating screw in addition to 
conduction from the electrical heating bands.  The efficiency of the 
feeding section is dependent upon the friction coefficient between the 
feed materials and the surface of the barrel and screw.  High friction 
along the barrel and low friction at the screw interface contribute to 
efficient mass flow in the feed section.  Obviously, the bulk density, 
particle shape, and compression properties of the raw materials impact 
the feeding efficiency.   
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The transfer of the material should be efficient in order to maintain 
an increase in pressure in the compression zone and the metering zone. 
The pressure rise in these zones insures efficient output of the extrudate.  
It is also possible to fine-tune the barrel temperature at the feeding 
section in order to optimize the friction at the surface of the barrel.  
Inconsistent material feed may result in a "surge" phenomenon that will 
cause cyclical variations in the output rate, head pressure and product 
quality.  The temperature of the melting zone is normally set 15 - 60ºC 
above the melting point of semi-crystalline polymers or the glass transition 
temperature of amorphous polymers [22, 24-26].   
The efficiency of the melting process depends on the polymer 
properties and the extruder design.  In general, polymers with low melt 
viscosities and high thermal conductivities exhibit a more efficient melting 
process.  Changes in the screw design are sometimes warranted to 
improve the melting process and improve mass flow through the extruder.  
Solidified polymer components can block the channel if melting is 
incomplete and result in a surge of material around the blockage. 
Processing conditions depend on the chemical stability and physical 
properties of the thermal polymer.  Melt viscosity, molecular weight, glass 
transition temperature, and melting point (in the case of a semicrystalline 
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polymer) should be considered to establish appropriate processing 
parameters.  Polymers are subjected to a mechanical shear stress 
imposed by the rotating screw, and thermal stress due to the relatively 
high processing temperatures and pressures.  Under these conditions, 
polymers may undergo chain scission, depolymerization or thermal 
degradation.  Differential scanning calorimetry, thermogravimetric analysis 
and gel permeation chromatography are often used to monitor polymer 
stability.  Plasticizers, antioxidants, thermal lubricants and other additives 
are often included in the formulation to address stability concerns. 
1.2.3  Wet Extrusion versus Dry Extrusion 
Based on the properties of the feed stock, extrusion processes can 
be classified as wet extrusion or dry extrusion.  In wet extrusion, the feed 
stock is conditioned and softened with the addition of solvents prior to 
processing.  The primary reason for wet extrusion is that extrudates have 
a superior finish due to the softening, plasticizing and ripening action of 
the solvents.  In some cases, such as cellulose nitrate, wet extrusion 
under low temperatures and pressures with minimum friction is required 
because the polymer is explosive when overheated using dry extrusion 
processes.   
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Compared with wet extrusion, dry extrusion is a solvent free 
process.  The feed stock is generally in solid form and heat is required to 
soften or melt the materials.  In the dry extrusion process, materials are 
softened by the heated barrel, the shearing effect of a rotating screw and 
friction during transit.  The extrudate solidifies after exiting the extruder.  
For obvious reasons, most of the extrusion processes use the dry 
technique.  
1.2.4  Mass Flow during Hot-Melt Extrusion 
Polymer melts behave as pseudoplastic fluids under typical 
processing conditions.  The viscosity of a pseudoplastic fluid depends 
upon the shear rate and is described by the following power law equation 
(Equation 1.1): 
h = K ´ g n-1
  (Equation 1.1) 
 
where h ?is the viscosity of the polymer melt, g is the shear rate, K is an 
exponential function of the temperature and depends on the properties of 
the polymer, and n is the power law constant (typically in the range of 
0.25 to 0.9 for the polymer melt).  
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Minimum temperatures are required for extrusion; otherwise, the 
torque required to rotate the screw will overload the drive unit.  Torque is 
directly proportional to melt viscosity.  The dependence of polymer melt 
viscosity on the temperature at a given shear rate follows the Arrhenius 
equation (Equation 1.2): 
h = K' ´ eEa/ RT    (Equation 1.2) 
 
In equation 1.2, K' is a constant depending on the structure and the 
molecular weight of the polymer; Ea is the activation energy of the 
polymer for the flow process, and it is a constant for the same type of 
polymer; R is the gas constant; and T is the temperature in degrees 
Kelvin. 
Heat conduction from the electrical bands on the barrel contributes 
to the melting process.  However, heat is also generated from shearing of 
the polymer melt.  “Viscous heat generation” is the process of 
transforming mechanical energy from shearing into thermal energy.  The 
rate of heat generation per unit volume due to the viscous heat 
dissipation follows Equation 1.3: 
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E = m ´ g n +1
   (Equation 1.3) 
 
in which m is a constant, g is the shear rate and n is the power law 
constant [24]. 
 
1.3  MATERIALS USED IN HOT-MELT EXTRUSION 
For a pharmaceutical material to be processed by hot-melt 
extrusion, it must be able to deform easily inside the extruder and solidify 
upon its exit.  The materials must meet the same levels of purity and 
safety as those prepared by traditional techniques.  Most of the raw 
materials used in hot-melt extruded pharmaceuticals have been used in 
the production of other solid dosage forms such as tablets, pellets, 
granules and transdermals.  Thermal stability of the individual compounds 
is a prerequisite for the process, although the short processing times 
encountered in this process may not limit all thermolabile compounds.   
Hot-melt extruded dosage forms are complex mixtures of active 
medicaments and functional excipients.  Functional excipients may be 
broadly classified as matrix carriers, release modifying agents, bulking 
agents, antioxidants, thermal lubricants and miscellaneous additives. The 
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selection and use of various excipients can impart specific properties to 
hot-melt extruded pharmaceuticals in a manner similar to those in 
traditional dosage forms. 
The incorporation of plasticizers may lower the processing 
temperatures necessary for hot-melt extrusion thus reducing drug and 
carrier degradation.  Drug release from these systems can be modulated 
by the incorporation of various functional excipients.  The dissolution rate 
of the active compound can be increased or decreased depending on the 
properties of the rate-modifying agent.  For systems that display oxidative 
or free radical degradation during processing or storage, the addition of 
antioxidants, acid acceptors, and/or light absorbers may be warranted. 
1.3.1  Carriers 
In hot-melt extruded drug delivery systems, the active compound is 
embedded in a carrier formulation comprised of one or more “meltable” 
substances and other functional excipients.  The meltable substance is 
generally a polymer or low melting point wax.  The selection of an 
appropriate carrier is important in the formulation and design of a hot-
melt extruded dosage form.  The properties of the carrier often dictate the 
processing conditions.  The physical and chemical properties of the carrier 
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can control the release of the active compound from the final dosage 
form.  Table 1.1 lists some of the carriers used to prepare hot-melt 
extruded dosage forms. 
For systems employing non-polymeric carrier materials, the 
compatibility between the drug substance and carrier should be 
addressed.  The incorporation of a low melting compound into a low 
melting point wax may form a eutectic mixture or reduce the melting 
point of the mixture preventing the formation of a solid dosage form.  The 
production of granules using carnauba wax has been reported [27-29].  
The granules contained diclofenac sodium and could be produced at 
temperatures less than the reported melting point of the wax material. 
The use of waxes and other wax-based materials have the potential 
advantage of being relatively inert. 
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Table 1.1  Carriers used to prepare hot-melt extruded dosage forms 
Chemical Name Trade Name Tg (°C) 
Tm 
(°C) References 
Ammonio methacrylate 
copolymer 
Eudragit® 
RS/RL 64 -- [3, 30, 31] 
Poly(dimethylaminoethylm
ethacrylate-co-methacrylic 
esters) 
Eudragit® E 50 -- [10, 14, 16] 
Poly(methyl acrylate-co-
methyl methacrylate-co-
methacrylic acid) 
7:3:1 
Eudragit® 
4135F 48 -- [4] 
Poly(methacrylic acid-co-
methyl methacrylate) 1:2 Eudragit
® S 160 -- [2] 
Hydroxypropyl cellulose Klucel® 130 -- [11-16, 29] 
Ethyl cellulose Ethocel® 133 -- [2, 3, 8, 32] 
Cellulose acetate butyrate CAB 381-0.5 125 157 [2, 3, 33] 
Cellulose Acetate 
Phthalate -- 165 192 [2, 34] 
Poly(ethylene oxide) Polyox® WSR -50 65-80 [5, 7, 9, 11-13] 
Poly(ethylene glycol) Carbowax® -20 37-63 [16, 35-39] [40] 
Poly(vinyl pyrrolidone) Kollidon® 168 -- [2, 38, 39, 41-43] 
Poly(vinyl acetate) Sentry® plus 35-40 -- [6, 33] 
Hydroxypropyl 
Methylcellulose Phthalate -- 137 150 [2, 44] 
Polyvinylpyrrolidone-co-
vinyl acetate 
Kollidon® 
VA64 -- -- [36, 38, 45] 
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Table 1.1 (continued) 
 
 
Hydroxypropyl 
Methylcellulose Methocel
® 175 -- [46] 
Hydroxypropyl 
Methylcellulose Acetate 
Succinate 
Aqoat-AS® -- -- [47] 
Poly(lactide-co-glycolide) PLGA -- -- [19, 20] 
Polyvinyl Alcohol Elvanol® -- -- [2] 
Chitosan Lactate Sea-Cure® -- -- [2] 
Pectin Obipektin® -- -- [2] 
Carbomer Carbopol
® 
974P 
-- -- [14, 16] 
Polycarbophil Noveon® AA-1 -- -- [14, 16] 
Poly(ethylene-co-vinyl 
acetate) 
Elvax® 40W -36 45 [3, 48, 49] 
Polyethylene -- -125 140 [10] [33] 
Poly(vinyl acetate-co-
methacrylic acid) CIBA-I -- 84-145 [50] 
Epoxy resin containing 
secondary amine 
CIBA HI 80-
100 
-- [50] 
Polycaprolactone -- -- -- [33] 
Carnauba Wax -- -- 82-85 [27-29] 
Ethylene-vinyl acetate 
copolymer Evatane
® -- -- [51] 
 25 
Table 1.1 (continued) 
 
 
 
Glyceryl Palmitostearate Precirol
® ATO 
5 -- 52 – 55 [46] 
Hydrogenated Castor & 
Soybean Oil Sterotex
® K -- -- [46] 
Microcrystalline Wax Lunacera
® 
Paracera® -- -- [52, 53] 
Corn Starch -- -- -- [54-56] 
Maltodextrin -- -- -- [53] 
Pregelatinized Starch -- -- -- [53] 
Isomalt Palatinit® -- 145-150 [57-59] 
Potato Starch -- -- -- [60, 61] 
Citric  
Acid -- -- 153 [62-64] 
Sodium Bicarbonate -- -- -- [62-64] 
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Drug release kinetics from hot-melt extruded dosage forms are 
highly dependent upon the choice of the carrier material.  Carriers used in 
hot-melt extruded dosage forms have included water insoluble polymers 
and waxes such as ethyl cellulose or carnauba wax in which the rate of 
drug release is diffusion controlled.  Water soluble polymers have included 
hydroxypropyl cellulose, polyethylene oxide, poly(vinyl pyrrolidone) in 
which the drug is released by a diffusion and erosion mechanism.  
Functional excipients have also been used to modify drug release rates in 
these systems.  Depending upon the physical and chemical properties of 
these additional excipients, various release profiles may be achieved.  
Functional excipients have been formulated into hot-melt extruded dosage 
forms to modify the drug release rate by altering the porosity or tortuosity 
of the dosage form.  Viscosity increasing agents have been incorporated 
into polymeric matrices to limit and reduce the initial burst often observed 
with these systems.  
The use of ionic and / or pH dependent polymers as the carrier 
matrix may achieve zero-order drug release or site specific drug delivery 
along the gastrointestinal tract.  Swelling agents and super disintegrants 
such as AcDiSolâ and Explotabâ have been investigated as a method to 
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modulate drug release.  It has been reported that Explotab® could be 
used as a “super-absorbent” in hydroxypropylcellulose hot-melt extruded 
transdermal films to facilitate moisture uptake in wound care applications 
[14].  A similar approach of drug release modification was applied to wax-
containing systems [27-29]. Hydroxypropylcellulose, Eudragitâ L, and 
sodium chloride were incorporated into diclofenac sodium/carnauba wax 
matrices.  Increasing the cellulose derivative or methacrylic acid 
copolymer concentration in the system resulted in a substantial increase in 
the release of diclofenac sodium. The release of diclofenac sodium from 
hydroxypropylcellulose/wax matrices was less pH dependent than the 
system containing wax/Eudragitâ L since the methacrylic acid copolymer 
is insoluble in water or in solutions with pH<6. The effect of sodium 
chloride was less pronounced and was attributed to the negligible swelling 
effect of this material.  
1.3.2  Plasticizers 
Plasticizers are typically low molecular weight compounds capable 
of softening polymers to make them more flexible.  The use of polymeric 
carriers in hot-melt extrusion often requires the incorporation of a 
plasticizer into the formulation to improve the processing conditions 
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during the manufacturing of the extruded dosage form or to improve the 
physical and mechanical properties of the final product.   
Plasticization of the polymer is generally attributed to the inter-
molecular secondary valence forces between the plasticizer and the 
polymer.  Plasticizers are able to decrease the glass transition temperature 
and the melt viscosity of a polymer by increasing the free volume between 
polymer chains.  In so doing, the ease of movement of polymer chains 
with respect to each other is dramatically reduced.  Plasticizers were also 
found to facilitate the fusion process of semi-crystalline polymers [65, 66].  
Less energy is usually required to melt semi-crystalline polymers following 
the addition of one or more plasticizers.  With the addition of a plasticizer, 
a hot-melt extrusion process can be conducted at lower temperatures and 
with less torque.  Both the active ingredient and the polymer will be more 
stable during the extrusion process due to these improved processing 
conditions.  Materials that are commonly used as plasticizers which are 
approved by the Food and Drug Administration for use in pharmaceutical 
dosage forms are listed in Table 1.2 according to their chemical structure. 
Plasticizers used for the preparation of pharmaceutical dosage 
forms must have good efficiency, stability, polymer – plasticizer 
compatibility and permanence.  Triacetin [3], citrate esters [10, 12], and 
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low molecular weight polyethylene glycols [3, 5, 12] have been 
investigated as plasticizers in hot-melt extruded systems.  Additionally, 
several drug substances have been reported to function as plasticizers in 
hot-melt extruded dosage forms [5, 7, 8, 10, 12]. 
The physical and mechanical properties and drug release rate of 
pharmaceutical dosage forms is dependent on the permanence of the 
plasticizers.  Permanence of a plasticizer during processing and storage is 
very important and the evaporation of highly volatile plasticizers from the 
dosage form during storage has been reported.  Arwidsson and coworkers 
[67] reported a dramatic change in drug release properties of coated 
tablets due to volatilization of the plasticizer during curing and storage.  
Repka and McGinity [12] demonstrated that the amount of plasticizer 
remaining in hot-melt extruded films over time was a function of the 
plasticizer type and storage conditions.  Plasticizers may also improve the 
physical-mechanical properties of hot-melt extruded dosage forms.  In 
transdermal films, the addition of a plasticizer to the polymer matrix can 
improve the film’s flexibility [10, 12].  Plasticizers often influence the 
product’s tensile strength and elastic modulus.   
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Table 1.2 Common plasticizers used in pharmaceutical dosage forms 
 
Type Examples 
Citrate esters triethyl citrate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate 
Fatty acid esters butyl stearate, glycerol monostearate, stearyl alcohol 
Sebacate esters dibutyl sebacate 
Phthalate esters diethyl phthalate, dibutyl phthalate, dioctyl phosphate 
Glycol derivatives Polyethylene glycol, propylene glycol 
Others triacetin, mineral oil, castor oil 
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1.3.3  Other Processing Aids 
The excessive temperatures needed to process unplasticized or 
under plasticized polymers may lead to polymer degradation.  The stability 
of polymers that are susceptible to degradation can be improved with the 
addition of antioxidants, acid receptors and or light absorbers during hot-
melt extrusion.  One manufacturer of these materials recommends the 
incorporation of an antioxidant into formulations containing low molecular 
weight hydroxypropylcellulose [68].  Similarly, polyethylene oxide has 
been reported to be protected from free radical and oxidative degradation 
by the incorporation of an antioxidant [7]. 
Antioxidants are classified as preventive antioxidants or chain-
breaking antioxidants based upon their mechanism.  Preventive 
antioxidants include materials that act to prevent initiation of free radical 
chain reactions.  Reducing agents, such as ascorbic acid, are able to 
interfere with autoxidation in a preventive manner since they 
preferentially undergo oxidation.  The preferential oxidation of reducing 
agents protects drugs, polymers and other excipients from attack by 
oxygen molecules.  These antioxidants are sometimes called oxygen 
scavengers.  They are most effective when used in a closed system where 
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oxygen can not be replaced once it is consumed.  Chelating agents such 
as edetate disodium (EDTA) and citric acid are another type of preventive 
antioxidant that decrease the rate of free radical formation by forming a 
stable complex with metal ions that catalyze these reduction reactions.  
Hindered phenols and aromatic amines are the two major groups of 
chain breaking antioxidants that inhibit free radical chain reactions.  
Commonly used antioxidants such as butylated hydroxyanisole, butylated 
hydroxytoluene and vitamin E are hindered phenols.  Because the O-H 
bonds of phenols and the N-H bonds of aromatic amines are very weak, 
the rate of oxidation is generally higher with the antioxidant than with the 
polymer.   
Other materials have been used to facilitate hot-melt extrusion 
processing.  Waxy materials like glyceryl monostearate have been 
reported to function as a thermal lubricant during hot-melt processing.  
Vitamin E TPGS has been reported to plasticize polymers and enhance 
drug absorption (Table 1.3). 
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Table 1.3  Common processing aids used in hot-melt extruded dosage 
forms 
Chemical Name Trade Name Refererence(s) 
Saccharose monopalmitate Sucroester [36, 43] 
Glycerolester and PEG esters Gelucire 44/14 [36] 
Glyceryl monostearate Imwitor [54-56] 
d-a-tocopherol 
(Vitamin E) -- [7] 
Vitamin E Succinate -- [7] 
Vitamin E TPGS -- [7, 13, 16] 
Butylated Hydroxy Anisole -- [7] 
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1.3.4  Drugs 
The properties of the active drug substance often limit the 
formulation and processing choices available to the pharmaceutical 
scientist in the development of dosage forms.  Hot-melt extrusion offers 
many benefits over traditional processing techniques.  The process is 
anhydrous which avoids potential hydrolytic degradation pathways.  In 
addition, poorly compactable materials can be prepared as tablets without 
the compression process.  Hot-melt extruded tablets can be produced by 
cutting an extruded rod to the desired dimensions.   
As an initial assessment, the thermal, chemical, and physical 
properties of the drug substance must be characterized.  Depending on 
the unique properties of the drug substance and the other materials in the 
formulation, the drug may be present as undissolved particles, a solid 
solution, or a combination in the final dosage form.  The state of the drug 
in the dosage form may have a profound impact on the processability and 
stability of the product.  The advantages and disadvantages of each form 
have been discussed in both injection molding [37] and melt extrusion 
[69] systems.  Solid dispersion systems may be more stable and more 
easily processed than solid solution systems, but solid solution systems 
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may be produced that are transparent and may have increased 
bioavailability of poorly soluble compounds.  Table 1.4 gives a partial 
listing of some of the drug substances that have been formulated and 
processed by hot-melt extrusion. 
The active compound may help or hinder the functionality of the 
other components in the formulation.  Oxprenolol hydrochloride was 
shown to melt under the hot-melt extrusion processing conditions thus 
decreasing the viscosity of the extrudate to yield a material with poor 
handling properties [3].  In similar work preparing dosage forms by 
injection molding, Cuff and Raouf reported that fenoprofen calcium 
inhibited the hardening of a PEG-MCC matrix, resulting in an unusable 
product [37].  In contrast, Lidocaine was shown to lower the glass 
transition temperature of Eudragitâ E/HDPE films [10], and 
hydrocortisone demonstrated a time dependent lowering of the glass 
transition temperature of HPC films [12].  Thus, the drug substance can 
be both beneficial or detrimental to properties of hot-melt extruded 
dosage forms. 
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Table 1.4  Drug Substances processed by hot-melt extrusion techniques. 
Drug Tm (°C) Reference(s) 
Nifedipine 175 [42, 44, 45] 
Indomethacin 162.7 [38, 42, 45] 
Piroxicam 204.9 [42] 
Tolbutamide 128.4 [42, 45] 
Lacidipine 184.8 [38, 42, 45] 
Chlorpheniramine Maleate 135 [5, 7, 12, 15, 30] 
Theophylline 255 [4, 6, 33, 54-56] 
17b-estradiol hemihydrate -- [36, 43] 
Oxprenolol hydrochloride -- [3] 
Fenoprofen calcium -- [37] 
Lidocaine -- [10] 
Hydrocortisone -- [12] 
Phenylpropanolamine 
Hydrochloride 
192 [46] 
Hydrochlorothiazide 274 [41, 58, 59] 
Carbamazepine 192 [35] 
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Table 1.4 (continued) 
 
 
Drug Tm (°C) Reference(s) 
Ibuprofen 76 [31, 32, 53] 
Melanotan-1  [19, 20] 
Diclofenac Sodium 284 [29] 
TAS 301  [70] 
Acetaminophen 170 [57] 
Nicardipine Hydrochloride 180 [47] 
Etonogestrel 200 [48, 49] 
Ethinyl estradiol 144 [48] 
Acetylsalicylic Acid 135 [60, 61] 
Diltiazem Hydrochloride 210 [3] 
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1.4  PROPERTIES OF HOT-MELT EXTRUDED DOSAGE FORMS 
1.4.1  Chemical Stability of Drug Substances during Hot-Melt 
Extrusion 
The stability of the active ingredients during hot-melt extrusion 
should be closely monitored since it is conducted at elevated 
temperatures.  Hydrolysis, solvolysis and oxidation are three primary 
mechanisms of drug degradation.  Drugs containing carboxylic acids, 
phosphoric acids or carbonyl functional groups are vulnerable to hydrolysis 
[71].  Water or a solvent must be present for hydrolysis or solvolysis to 
occur.  Since hot-melt extrusion is a solvent free process, hydrolysis and 
solvolysis are often not a concern.  Oxidation is also a free-radical chain 
reaction with three distinctive stages: initiation, propagation and 
termination.  Oxidative drug degradation during hot-melt extrusion has 
been reported by Aitken-Nicol [10] and Repka [12].   Peroxides formed 
due to the oxidation of polymeric carrier were shown to induce the 
oxidation of the active ingredient [72].  Since the drug and polymer share 
the same oxidation mechanisms, antioxidants for polymers discussed in 
the previous chapter are also applicable for active ingredients. 
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High-pressure liquid chromatography is the most commonly used 
technique to investigate the stability of drug substances.  Stability 
indicating methods should be developed so that the active ingredient is 
separated from the degradants.  The purity of drug peak can be studied 
using a photo diode-array detector to confirm the reliability of the assay.   
1.4.2  Thermal and Crystalline Properties of Hot-Melt Extruded 
Dosage Forms 
Drug and polymers are subjected to elevated temperatures, high 
pressure and intense mixing during the hot-melt extrusion process.  At 
these elevated temperatures, the solubility of the drug in the polymer 
carrier is increased.  Depending upon the processing conditions, some 
crystalline drugs either melt or become solubilized in the polymer matrix 
during the process.  Recrystallization and nucleation of drug molecules 
from the polymer melt is retarded during the cooling of the extrudate due 
to reduced solute migration and the difficulty in nucleation in a highly 
viscous polymer medium.   Furthermore, polymer viscosity increases 
dramatically with the decrease in the temperature.    
Following hot-melt extrusion, the active ingredient can be present 
in one of two forms: as a crystal embedded in the hardened polymer 
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phase, or as individual molecules dissolved in the polymer matrix.  
Formation of a drug-polymer solid dispersion in hot-melt extruded dosage 
forms has been reported [6, 10].  Complexation between drug and 
polymer may also contribute to the formation of a solid solution [73].  
Solid solutions containing the drug and an amorphous polymer are 
generally regarded as interstitial solid solutions where drug molecules 
occupy the interstitial space between the polymer chains.  For a semi-
crystalline polymer, some drugs were reported to be concentrated in the 
amorphous regions of the polymer [74], and some drugs were reported to 
be solubilized in the crystalline matrix of the polymer [75].  Because the 
drug is dispersed at a molecular level, a solid dispersion is a metastable 
form.  It is susceptible to aging effect and the drug may recrystallize from 
the matrix during the storage under elevated temperature and high 
humidity.   Crystallization of chloramphenicol palmitate from the solid 
dispersion in PVP was reported [75]. 
The methods that have been used to characterize hot-melt 
extrudates are summarized in Table 1.5.  In addition to characterizing the 
hot-melt extrudate, these methods can be used to differentiate between 
solid solutions (molecularly dispersed drug), solid dispersions in which 
drug is only partly molecularly dispersed and physical mixtures of drug 
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and carrier.  It is challenging to precisely characterize systems which are 
molecularly dispersed from those that are not due to the complexity of the 
systems, and different analytical methods may yield contrasting results.  
In general, dispersions in which no crystallinity can be detected are 
molecularly dispersed and the absence of crystallinity is used as a criterion 
to differentiate between solid solutions and solid dispersions. 
Thermoanalytical methods include those that examine the system 
as a function of temperature.  Differential scanning calorimetry (DSC) has 
been widely used to study the thermal properties of materials used in hot-
melt extrusion.  DSC can be used for the quantitative detection of 
transitions (melting point, glass transition) in which energy is required or 
liberated (i.e. endothermic and exothermic phase transformations).  
Generally, the hot-melt extrudate is scanned and compared to a physical 
mixture of the drug, polymeric carrier and other excipients.  The lack of a 
melting transition in the DSC scan of the hot-melt extrudate indicates that 
the drug is present in an amorphous rather than crystalline form.  
Thermogravimetric analysis (TGA) is a measure of thermally induced 
weight loss of a material as a function of applied temperature.  TGA is 
limited to studies involving either a weight gain or loss, and is commonly 
used to study desolvation and decomposition.  TGA can be used as a 
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screening tool for the thermal stability of materials used in hot-melt 
extrusion.  Microthermal analysis has been used to identify phase 
separation in hot-melt extrudates containing itraconazole and Eudragit 
E100 [76].  In this approach, differences in the thermal topography of 
hot-melt extrudates can be discerned. 
X-ray diffraction (XRD) is also used to characterize the crystalline 
properties of hot-melt extruded dosage forms.  The principle of XRD is 
based on Bragg’s law, in which parallel incident X-rays strike the crystal 
planes and are then diffracted at angles related to the spacing between 
the planes of molecules in the lattice.  Crystallinity is reflected by a 
characteristic fingerprint region in the diffraction pattern.  If the 
fingerprints of the drug and carrier do not overlay one another, the 
crystallinity of the drug and polymer following hot-melt extrusion can be 
determined.  Thus, X-ray diffraction can be used to differentiate between 
solid solutions, in which the drug is amorphous, and solid dispersions, in 
which it is at least partly present in the crystalline form, regardless of 
whether the carrier is amorphous or crystalline.  However, the sensitivity 
of the XRD technique is limited and cannot generally detect crystallinity of 
less than 10% [77].  
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Infrared spectroscopy can be used to detect changes in bonding 
between functional groups due to structural changes or a lack of crystal 
structure.  IR can be used to differentiate between peaks that are 
sensitive to changes in crystallinity from those that are not [78].  Solid 
state nuclear magnetic resonance (NMR) has been used to probe the 
crystallinity of materials.  Although any NMR-active nucleus can be 
studied, most efforts have focused on 13C investigations.   
Microscopy is one of the best methods to study the crystalline 
properties of hot-melt extrudates.  Both optical and electron methods are 
suitable to examine the surface morphology of samples to probe for the 
presence of crystalline particles or amorphous domains.  It is also possible 
to obtain reliable particle size information using these techniques.    
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Table 1.5:  Common Methods used for the characterization of hot-melt 
extrudates. 
 
 
Thermoanalytical Methods 
Differential Scanning Calorimetry 
Thermogravimetric Analysis 
Hot Stage Microscopy 
Microthermal Analysis 
Dissolution Testing  
X-Ray Diffraction Wide Angle X-Ray Diffraction 
Spectroscopic Methods IR 
Microscopic Methods 
Polarized Light Microscopy 
Scanning Electron Microscopy 
Transmission Electron Microscopy 
Atomic Force Microscopy 
Nuclear Magnetic Resonance 
Magic Angle Spinning Techniques 
Cross-Polarization Techniques 
Mechanical Analysis 
Tensile Strength 
Elongation 
Young’s Modulus 
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1.5  HOT-MELT EXTRUDED DOSAGE FORMS 
1.5.1  Granules, Pellets & Spheres 
Until recently, hot-melt extrusion had not received much attention 
in the pharmaceutical literature.  Rippie and Johnson prepared pellets 
containing cellulose acetate phthalate using a rudimentary ram extruder in 
1969 to study the dissolution rates based upon pellet geometry [34].  
More recently, Mank and coworkers reported in 1989 and 1990 on the 
extrusion of a number of thermoplastic polymers to produce sustained 
release pellets [79, 80].    
Follonier and coworkers in 1994 investigated the possibility of using 
hot-melt extrusion technology to produce sustained-release pellets [3].  It 
was the researchers’ goal to prepare a dosage form in a simple and 
continuous manner.  Thermal degradation was recognized as a limitation 
of this hot-melt process.  Diltiazem hydrochloride, a relatively stable and 
freely soluble drug was incorporated into their polymer–based pellets for 
sustained release capsules.  Polymers and plasticizers were selected prior 
to extrusion to maximize the possibility of a successful dosage form.  In 
their study, ethyl cellulose, cellulose acetate butyrate, poly(ethyl 
acrylate/methyl-methacrylate/trimethyl ammonio ethyl methacrylate 
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chloride) (Eudragit® RSPM) and poly(ethylene-co-vinyl acetate) (EVAC) 
were the polymers and the plasticizers were triacetin and diethyl 
phthalate.  The porosity of the pellets was determined by mercury 
porosimetry.  The pellets exhibited a smooth surface and low porosity.   
The drug release characteristics of diltiazem were biphasic, with the CAB 
and EVAC pellets giving the slowest release rate.  These researchers also 
reported that the type and amount of plasticizer used, drying time of the 
polymers, extrusion temperatures, and plasticization times varied with 
each formulation.  They observed that the stability of Eudragit® RSPM was 
adequate for extrusion at a temperature of 130°C.   
In a latter study, Follonier, et al. examined different parameters 
influencing the release of diltiazem hydrochloride from hot-melt extruded 
pellets incorporated into hard gelatin capsules [2].  The drug release rate 
was found to depend upon polymer type, addition of pore-forming 
additives or hydrophilic polymers, and pellet size.  The authors obtained in 
vitro release rates low enough to achieve therapeutic plasma levels for 
diltiazem hydrochloride with a once or twice daily administration.  The 
addition of hydrophilic polymers helped avoid incomplete drug release due 
to encapsulated drug clusters in the insoluble matrix.  The authors also 
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incorporated various polymeric excipients, such as croscarmellose sodium 
(Ac-Di-Sol®) and sodium starch glycolate (Explotab®), into the pellet 
formulations to vary the drug release rate.  The incorporation of swelling 
agents was able to reduce the initial burst release from the matrix. 
In 1996 and 1997, Miyagawa, Sato, and coworkers prepared 
controlled release matrices containing diclofenac as a model drug by hot-
melt extrusion [27-29].  The authors used a twin-screw compounding 
extruder to prepare wax matrix granules composed of carnauba wax, the 
model drug, and other rate controlling agents.  Their study showed that a 
wax matrix with high mechanical strength could be obtained even when 
the composition was processed below the melting point of the wax.  
Dissolution of diclofenac from the wax matrix granules was strongly 
influenced by the formulation.  Hydroxypropylcellulose, methacrylic acid 
copolymer (Eudragit L-100), and sodium chloride were investigated as 
dissolution rate controlling materials.  The authors emphasized the 
advantages of using the twin-screw extruder for wax matrix tablets 
because of the low processing temperatures, high kneading and 
dispersing ability, and short residence time.  The authors observed in their 
second study that the selection of rate controlling excipients based upon 
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solubility and swelling characteristics had a significant impact on drug 
release properties from the wax matrix granules. 
Liu and coworkers [46] compared the properties of wax based 
granules and tablets prepared by hot-melt extrusion to those prepared by 
high shear melt granulation.  Powder blends containing 
phenylpropanolamine hydrochloride, Precirolâ, Sterotexâ K, and various 
excipients (microcrystalline cellulose, lactose and Emcompressâ) were 
extruded using a single screw extruder with open end discharge.  The 
extrudates were then passed through a 14-mesh screen to form granules.  
Hot-melt extruded granules were observed to be less spherical than high-
shear melt granules and had lower bulk and tap densities.  Analysis of the 
hot-melt extruded granules showed better drug content uniformity among 
granules of different size ranges compared with high-shear melt granules, 
resulting in a more reproducible drug release from the corresponding 
tablets.  At the same wax level, drug release from tablets decreased in the 
order of using microcrystalline cellulose, lactose and Emcompressâ as the 
filler excipient. The observed differences in the dissolution properties of 
the tablets were due to the differences in the solubility, swellability and 
density of the filler excipients. 
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Hot-melt extrusion has also been used to prepare effervescent 
granules [62-64, 81-84].  Lindberg and coworkers prepared effervescent 
granules using a twin-screw extruder.  During extrusion, sodium 
bicarbonate and anhydrous citric acid were added from separate inlet 
ports of the extruder, and ethanol was added as a liquid binder and 
pumped through a nozzle in the extruder barrel to facilitate the formation 
of the granules. 
Koleng and McGinity utilized hot-melt extrusion technology for the 
preparation of rapid release granules [40].  A hot-melt extrusion process 
was used to granulate acetaminophen and filler excipients with low 
molecular weight poly(ethylene glycol)s.  The resultant granules were 
then combined with additional excipients (disintegrants and lubricant) and 
compressed into tablet compacts.  The granules exhibited improved drug 
release compared to the tablets.  Tablets containing 15% poly(ethylene 
glycol) released greater than 80% of the incorporated acetaminophen 
after 30 minutes, as required for acetaminophen tablets in the USP 23. 
Zhang investigated the properties of poly(vinyl acetate) as a carrier 
for theophylline from matrix dosage forms prepared by hot-melt extrusion 
[6].  The influence of granule size and drug loading level on the drug 
release properties and the thermal stability of poly(vinyl acetate) (PVAc) 
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were investigated.  The rod shaped extrudates were ground and then 
compressed into tablets with various combinations of microcrystalline 
cellulose.  As the size of the hot-melt extruded theophylline/PVAc granules 
was increased, a significant decrease in the release rate of the 
theophylline was observed.  Since the drug was released from the matrix 
by a diffusion mechanism, the decrease in the drug release rate from the 
tablets containing larger granules was concluded to be a result of a longer 
diffusion pathway.  PVAc was found to have a high solids carrying capacity 
when processed by hot-melt extrusion, with drugs loads as high as 50%.  
The authors also studied the stability of PVAc to shear and stress using a 
Plasticorder® rheometer.  The torque gradually decreased as the 
temperature of the polymer melt in the chamber was increased.  No 
further change in the torque was observed after the initial heating step.  
This finding confirmed that PVAc was not susceptible to degradation by 
either thermal or shearing stress under the processing conditions.  
Hot-melt extrusion has been used to prepare solid dispersions for 
immediate and sustained release applications.  It has also been used to 
prepare solid dispersions in which the drug dissolution rate is enhanced.  
Huslman and coworkers demonstrated the hot-melt extrusion technique to 
increase the solubility rate of 17-Estradiol hemihydrate, a poorly water-
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soluble drug [36, 43, 85].  The authors used PEG 6000, PVP or a 
vinylpyrrolidone – vinylacetate copolymer as polymers with Sucroester 
WE15 or Gelucire 44/14 as functional excipients.  Rods were extruded, cut 
into granules and then compressed into tablets.  The solid dispersions 
exhibited a significant increase in dissolution rate compared to the pure 
drug or to the physical mixtures.  A 30-fold increase in dissolution rate 
was obtained from a formulation containing 10% 17-Estradiol, 50% PVP 
and 40% Gelucire 44/14.   
Young and coworkers successfully prepared spherical controlled 
release theophylline pellets by a hot-melt extrusion (HME) and 
spheronization process [4].  A powder blend of anhydrous theophylline, 
Eudragit® Preparation 4135 F, microcrystalline cellulose and polyethylene 
glycol 8000 powder was sieved, blended and then melt-extruded in a 
Randcastle Microtruder®.  The hot-melt extruded pellets were prepared by 
first cutting a thin, extruded composite rod into symmetrical pellets.  The 
pellets were then spheronized in a traditional spheronizer at elevated 
temperatures.  The melt-extruded matrix pellets exhibited diffusion-
controlled drug release.  Drug release from the acrylic matrix system was 
influenced by the pH of the dissolution medium since the solubility of the 
matrix polymer, Eudragit® Preparation 4135 F, is pH dependent.  The 
 52 
surface morphology of the pellets was found to depend upon the 
spheronization parameters.  
1.5.2  Tablets 
Prapaitrakul and coworkers prepared disks using a melt extrusion 
method in which the molten materials were forced into a mold [86].  The 
disks contained glyceryl fatty acid esters (Gelucire), polyethylene glycol 
fatty acid esters, or a combination of the two with chlorpheniramine 
maleate as a model drug.  The release of the drug into distilled water, pH 
1.2 buffer, and pH 7.5 buffer exhibited square root of time dependence.  
An increase in the fatty acid ester hydrophilic-lipophilic balance (HLB) from 
1 to 14 resulted in a 10-fold increase in the drug release rate.  The 
maximum release rate was seen from the fatty acid ester with a melting 
point of 44°C.  The pH of the dissolution medium had a minimal impact on 
the rate of drug release.  The release rate was modified by blending 
Gelucires of different melting points and HLB values. 
In a later study, these researchers prepared disks containing 
polyethylene, polycaprolactone, polyvinyl acetate, and cellulose acetate 
butyrate with theophylline as a model drug at a 50% loading [33].  The 
authors reported an 8 fold difference in the effective diffusion coefficient 
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between the various polymers.  The effective diffusion coefficient 
increased 10-fold when the theophylline load was increased from 50 to 
70% in the polycaprolactone and polyethylene disks.  Disks with 
theophylline content greater than 70% by weight could not be made.  The 
release rate was modified using soluble additives (sucrose, sodium 
chloride, Pluronicâ and PEG).   
Zhang and McGinity describe a novel method to prepare sustained 
release matrix tablets directly from a single screw hot-melt extruder [5, 
9].  These researchers studied the properties of polyethylene oxide (PEO) 
as a drug carrier and studied the release mechanism of chlorpheniramine 
maleate (CPM) from matrix tablets.  Large diameter rods (4.5 mm) were 
extruded and cut into tablets.  PEG 3350 was included as a plasticizer to 
facilitate processing.  The stability of the primary polymer, PEO, as a 
function of processing temperature was determined using gel permeation 
chromatography.  The authors report that polymer type, temperature, and 
residence time in the extruder impacted the PEO stability.  In addition, the 
researchers showed that additional mixing of the components occurred in 
the barrel of the extruder, since the content uniformity of the extruded 
tablets was within 99.0% to 101.0% of the theoretical content.  As the 
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PEG 3350 concentration increased, the release of CPM from the extruded 
matrix tablets was found to increase.  The rate of hydration and 
dissolution rate of the entire matrix system were thus accelerated due to 
the presence of the plasticizer.  The rate of drug release was only slightly 
affected by changes in drug content until the drug loading reached 20%.  
Crowley and coworkers studied the thermal stability of polyethylene 
oxide (PEO) in sustained release tablets prepared by hot-melt extrusion 
[7].  The weight average molecular weight of the polymer was determined 
using gel permeation chromatography.  The chemical stability of PEO was 
found to be dependent on both the storage and processing temperature, 
and the molecular weight of the polymer.  Storage of the polymer above 
its melting point significantly increased polymer degradation, and the 
degradation process was accelerated as the molecular weight of the 
polymer was reduced.  The thermal stability of high molecular weight PEO 
(1,000,000 or PEO 1M) in sustained release chlorpheniramine maleate 
(CPM) tablets prepared by hot-melt extrusion was found to depend on the 
processing temperature and screw speed.  Lower molecular weight PEO 
(100,000 or PEO 100K) was demonstrated to be a suitable processing aid 
for PEO 1M.  Incorporation of PEO 100K reduced degradation of PEO 1M 
and did not alter the release rate of CPM.  Vitamin E, Vitamin E Succinate 
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and Vitamin E TPGS were found to be suitable stabilizers for PEO, 
however, ascorbic acid was shown to degrade the polymer in solution.  
Thermal analysis demonstrated that Vitamin E Succinate and Vitamin E 
TPGS were dispersed at the molecular level in hot-melt extruded tablets.  
Solubilized Vitamin E Succinate and Vitamin E TPGS suppressed the 
melting point of the polyethylene oxide.  Drug release rates from hot-melt 
extruded tablets stabilized with antioxidants were found to be dependent 
on the hydrophilic nature of the antioxidant. 
Another unique application of the hot-melt extrusion technique is 
reported by Nakamichi and coworkers at Nippon Shinyaku Company [47].  
The authors prepared a floating sustained release dosage form composed 
of nicardipine hydrochloride and hydroxypropyl methylcellulose acetate 
succinate using a twin screw extruder.  Rods were extruded and then cut 
into tablets of different sizes.  A dosage form with very small and uniform 
pores was obtained by selecting a screw that generated high pressure 
near the die, and by adjusting the processing temperatures.  The authors 
demonstrated that the extruded, floating enteric polymer system was 
retained in the stomach for up to 6 hours. 
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1.5.3  Transdermal and Transmucosal Films 
Currently, films for transdermal / transmucosal drug delivery and 
wound care applications are produced most frequently by casting from 
organic or aqueous solvents [10].  However, there are several problems 
with the casting technique.  Gutierrez-Rocca and McGinity showed that 
physical aging of both aqueous and solvent cast acrylic films resulted in a 
decrease in elongation or elasticity and an increase film tensile strength 
[87].  This mechanical instability was related to the relaxation of the 
polymer chains as they moved toward a state of equilibrium.  Also, it has 
been demonstrated that the type and level of plasticizers, curing time, and 
temperature have a significant effect on the dissolution rate of drugs from 
films formed from aqueous dispersions [88, 89].    
Aitken-Nichol and coworkers investigated the viability of hot-melt 
extrusion technology in 1996 for the production of thin, flexible acrylic 
films for topical drug delivery [10].  The authors noted that the 
manufacturing process was not restricted by solvent concerns.  The 
authors compared cast films with hot-melt extruded films.  Eudragit® E100 
was the primary thermoplastic polymer extruded.  The authors reported 
that hot-melt extrusion was a viable technology for the production of free 
films of this acrylic resin.  Although triethyl citrate was an acceptable 
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plasticizer for this polymer, these researchers found that lidocaine 
hydrochloride also plasticized for the acrylic films.  The authors concluded 
that the differences in the dissolution rate and ductile properties between 
cast films and extruded films were due to the amount of drug dissolved in 
the polymer. 
Repka and coworkers discussed the numerous disadvantages of 
solvent casting methods for preparing transdermal films [12].  These 
researchers produced hydroxypropylcellulose films using a Killion hot-melt 
extruder.  Several plasticizers and two model drugs were incorporated into 
the HPC films.  The influence of the plasticizers and drugs on the physical-
mechanical properties of the films was investigated.  The authors found 
that HPC films could not be produced without a plasticizer due to high 
torque levels on the extruder.  All plasticizers examined in this study were 
found to be stable under the study processing conditions except PEG 400.  
The influence of processing temperature and storage time on the two 
model drugs (chlorpheniramine maleate and hydrocortisone) was also 
investigated.  Chlorpheniramine maleate proved to be an excellent 
plasticizer for hydroxypropyl cellulose.  The hot-melt extruded films were 
found to be mechanically and chemically stable for up to 12 months.  The 
authors also reported that chlorpheniramine maleate was fully dissolved in 
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the hydroxypropyl cellulose film up to the 10% level.  Hydrocortisone was 
also found to be a good plasticizer, however, its chemical stability was 
found to be a function of processing temperature and residence time in 
the extruder. 
Repka, et al. also reported that the mechanical properties of the 
films depended on whether the testing was performed perpendicular to 
flow from the extruder or in the direction of flow from the extruder.  All 
extruded films exhibited a decrease in tensile strength and a large 
increase in percent elongation when testing was performed perpendicular 
to flow versus in the direction of flow.  These results were in contrast to 
those reported by Aitken-Nichol [10].  The cause of the discrepancy 
between the two studies is likely due to polymer compatibility between 
polyethylene and Eudragit E100 in the Aitken-Nichol study.  However, 
these studies illustrate how “flow orientation” can impact the mechanical 
properties of hot-melt extruded delivery systems. 
Repka and McGinity prepared films containing hydroxypropyl 
cellulose and polyethylene oxide by hot-melt extrusion with and without 
Vitamin E TPGS as a formulation additive [13].  Addition of 1, 3, and 5% 
Vitamin E TPGS decreased the glass transition temperature of the 
extruded films containing either a 50:50 or 80:20 ratio of HPC to PEO in 
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an almost linear fashion.  The glass transition temperature of the film 
containing 3% Vitamin E TPGS was lowered by over 11ºC compared to 
the film without Vitamin E TPGS.  The films containing 3% Vitamin E TPGS 
had similar mechanical properties to films containing 3% PEG 400, but a 3 
fold increase in percent elongation was observed compared to films 
containing 3% triethyl citrate and 3% acetyltributyl citrate.  Vitamin E 
TPGS also facilitated the processing of the HPC/PEO films by decreasing 
the barrel pressure, drive amps, and torque of the extruder. 
Researchers at Johnson & Johnson disclose a bioadhesive hot-melt 
extruded film for intra-oral drug delivery [90].  These films may also be 
used for transmucosal drug delivery or transdermal systems.  The films 
may be produced separately and layered after extrusion, or in some 
cases, a multi-layered system may be co-extruded in a continuous 
process.  Currently, a marketed denture adhesive is prepared by hot-melt 
extrusion using thermoplastic polymers that adhere to the mucous 
membrane when wetted.  A bioadhesive film has the benefit of simplifying 
dosage form design and reducing preparation costs, due to the elimination 
of the adhesive layer in the system.  It is desirable for the film to have 
adequate adhesion strength so that retention of the film at the application 
site can be achieved.   
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Repka and McGinity conducted bioadhesion testing of hot-melt 
extruded hydroxypropyl cellulose films containing various additives on 
human subjects using a Chatillon testing apparatus [14].  These 
researchers found that force of adhesion, elongation at adhesive failure, 
and modulus of adhesion were a function of the type of additive in the 
extruded film.  The force of adhesion was highest for the films containing 
carbomer (Carbopol® 971P) and polycarbophil (Noveon AA-1®).  This 
study demonstrated that a single layer HPC film could be produced with 
the bioadhesive incorporated into the matrix, thus eliminating a separate 
“adhesive layer” and simplifying the process of transdermal and 
transmucosal delivery systems. 
1.5.4  Implants 
Rothen-Weinhold and coworkers prepared long-acting poly(lactic 
acid) implants containing vapreotide, a somatostatin analogue, by hot-
melt extrusion [18].  Many peptides are susceptible to degradation and it 
is difficult to formulate and deliver them without significant loss of 
biological activity.  Furthermore, the authors desired to deliver the peptide 
for a period of weeks in a controlled manner.  However, the authors 
reported that the peptide degraded during manufacturing.  The main 
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degradation product obtained after implant manufacturing was found to 
be a lactoyl lactyl-vapreotide conjugate.  The researchers studied the 
influence of residual lactide in the polylactic acid on the formation of 
peptide impurities during manufacturing.  This report illustrated how the 
purity of the carrier can impact the quality of the dosage form. 
Melanotan-I (MT-I) release rates from biodegradable implants of 
poly(D,L lactide-co-glycolide) (PLGA) copolymer prepared by melt 
extrusion have been reported [19, 20].  The in-vitro release of MT-I 
exhibited a triphasic profile with an initial rapid release followed by a 
secondary phase of slow release, then a tertiary phase of rapid release 
due to erosion of the polymer.  The initial rapid release observed with 
PLGA (50:50 molar ratio of lactic/glycolic acid) polymers was less than 5% 
of the drug load and the tertiary phase commenced after about 3 weeks.  
The factors controlling the drug release were polymer degradation and 
erosion which were controlled by the physical properties of the polymer 
such as molecular weight and viscosity.  
A contraceptive vaginal ring containing polyethylene vinylacetate 
copolymers, etonogestrel and ethinyl estradiol was prepared by melt 
extrusion [48].  The powders were compounded in a twin-screw extruder, 
granulated and then spun into fibers.  After leaving the extruder, the 
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strands were cooled to room temperature and granulated using a strand 
granulator.  The steroids were completely dissolved in the polymer melt.  
A co-extrusion procedure was used to prepare the coaxial fibers in which 
two single screw extruders were connected to a spinning block.  The 
molten polymers were delivered to two gear pumps which were necessary 
to provide precise flow control of both polymers to the spinneret.  Finally, 
the membrane and core polymers were combined in the spinneret to form 
the coaxial fiber. 
Implants composed of block copolymers have also been studied.  
Witt and coworkers investigated the degradation of ABA triblock 
copolymers, consisting of poly(lactide-coglycolide) A-blocks and 
poly(oxyethylene) B-blocks, and PLG, poly(lactide-co-glycolide), with 
respect to swelling behavior, molecular weight loss and polymer erosion.  
Implants were prepared by either compression molding or extrusion using 
a laboratory ram extruder.  Insertion of an elastic B block did not lower 
the processing temperature, although the entanglement of the polymer 
chains was significantly reduced.  In this report, the influence of implant 
geometry was found to be insignificant. 
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1.6  QUALITY CONTROL AND REGULATORY CONSIDERATIONS 
Pharmaceutical products prepared by hot-melt extrusion have been 
approved in the United States, Europe and Asia [91].  Comprehensive 
documentation of the process monitoring and control devices is easily 
accomplished.  These parameters include feed rate, temperature, screw 
speed, pressure, melt viscosity, drive amperage and torque.  Cleaning is 
accomplished by disassembly and removal of any excess material from the 
screw, barrel and die.  These surfaces can then be swabbed and analyzed 
to satisfy cleaning validation requirements. 
 
1.7  A VIEW TO THE FUTURE 
Hot-melt extrusion technology is an attractive process for the 
manufacture of drug delivery systems.  A wide range of dosage forms and 
applications from oral to topical and parenteral can be prepared.  Solid 
dispersions and / or solid solutions of the drug embedded in the carrier 
matrices may allow for sustained release application and dissolution rate 
improvement.  Solvents are not required and a broad selection of carriers 
and functional excipients are available. 
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High process temperatures and shear forces are the primary 
drawbacks of this process technology.  However, these challenges can be 
overcome by formulation and engineering approaches.  Selection of low 
melting carriers or the use of compatible plasticizers can reduce process 
temperatures.  Extruder and screw design can also reduce the likelihood 
of drug or carrier degradation by reducing the shear forces or residence 
time.  Given these considerations, even drugs known to be thermally labile 
can be processed.   
Interest in hot-melt extrusion is increasing.  The published 
literature reveals innovative and promising new approaches to drug 
delivery systems like effervescent granules, fast dissolving systems, 
complex formation and solid dispersions.  This process allows for precise 
delivery of drug loads based upon the size and shape of the extrudate. 
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CHAPTER 2  RESEARCH OBJECTIVES 
 
2.1  OVERALL OBJECTIVES 
The objectives of this study were to investigate the properties of 
water soluble and water insoluble polymers as carriers for hot melt 
extruded dosage forms.  The physicochemical and mechanical properties 
and the mechanisms of drug release of the hot-melt extruded dosage 
forms were also studied.  The influence of processing conditions and 
formulation variables on the properties of hot-melt extruded dosage forms 
were also determined.   
 
2.2  SUPPORTING OBJECTIVES 
2.2.1  Investigate the Stability of Polyethylene Oxide in Matrix 
Tablets Prepared by Hot-Melt Extrusion  
Hot-melt extrusion of a thermoplastic polymer is generally 
conducted at 15 – 60°C above the melting point of the polymer.  During 
hot-melt extrusion, polymers are subject to mechanical, thermal and 
oxidative degradation.  Mechanical degradation may be induced by the 
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shear effects imposed by the rotating screw.  Thermal depolymerization 
results from high temperatures and includes random scission, scission 
from the ends of the polymer and unzipping of substitute groups.  
Oxidative degradation is the result of a chemical reaction between oxygen 
molecules and the polymer.  Therefore, the thermal stability of PEO (MW 
= 1,000,000 or PEO 1M) in sustained release chlorpheniramine maleate 
tablets prepared by the hot-melt extrusion process was investigated.  Gel 
permeation chromatography was used to determine the molecular weight 
of the polymer before and after hot-melt extrusion.  The influence of 
processing conditions (temperature and screw speed) on polymer stability 
was studied.  Low molecular weight PEO (MW = 100,000 or PEO 100K) 
was incorporated as a plasticizer to facilitate processing and antioxidants 
were included to stabilize the polymer.  The influence of processing 
parameters and incorporation of a plasticizer and antioxidants on the drug 
release properties of the tablet was also investigated.  Finally, the 
chemical stability of PEO under accelerated storage conditions (40ºC, 
60ºC and 80ºC all at 75% relative humidity) was determined. 
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2.2.2  Characterize the Physicochemical Properties and 
Mechanism of Drug Release from Ethyl Cellulose Matrix 
Tablets prepared by Direct Compression and Hot-melt 
Extrusion 
The physicochemical properties of the extruded dosage forms 
including drug release properties, crystalline properties, polymer-drug 
miscibility and polymer-drug interaction have been characterized using 
differential thermal analysis, X-ray diffraction and scanning electron 
microscopy.  Since hot-melt extrusion is conducted at an elevated 
temperature, a crystalline drug substance can either be dispersed at the 
molecular level or dispersed as individual particles in the hot-melt 
extruded polymer matrix.  The crystallinity of the drug substance following 
hot-melt extrusion is reported.  The influence of the dissolved drug 
molecules on the thermal properties of the polymeric carriers will also be 
determined.   Since the polymeric carrier is molten and pressurized inside 
the extruder, the hot-melt extrudate is anticipated to possess a lower 
porosity and higher tortuosity than tablets prepared by direct compression 
methods.  A comparison of the physicochemical properties of dosage 
forms prepared by hot-melt extrusion with those prepared by direct 
compression technique has been conducted using a novel analytical 
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technique.  Finally, the mechanism of drug release is related to the 
physical properties of the tablets.  
2.2.3  Investigate the Influence of Guaifenesin and Ketoprofen 
on the Mechanical Properties of Hot-melt Extruded 
Polyethylene Oxide Films 
The feasibility or producing transdermal and transmucosal films 
containing low molecular weight polyethylene oxide was investigated.  
Several transdermal systems use a polymeric carrier as a drug depot.  
However, little has been reported in the literature on the effect of the 
drugs on the physical and mechanical properties of the resultant films.  In 
this study, guaifenesin and ketoprofen were selected to investigate their 
influence on the stability of hot-melt extruded polyethylene oxide films.  
The thermal properties of the hot-melt extruded films were investigated 
using differential scanning calorimetry.  Scanning electron microscopy was 
used to examine the surface morphology of the films, and wide angle x-
ray diffraction was used to investigate the crystalline properties of the 
polymer, drugs and physical mixtures and the solid state structure of the 
films.  The stability of the polymer was studied using gel permeation 
chromatography.  The mechanical properties, including percent elongation 
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and tensile strength of the films were determined on an Instron according 
to ASTM procedures.   
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CHAPTER 3  AN INVESTIGATION OF THE STABILITY 
OF POLYETHYLENE OXIDE IN MATRIX TABLETS 
PREPARED BY HOT-MELT EXTRUSION 
 
* Reprinted with permission from Crowley, M. M., Zhang, F., Koleng, J. J., 
and McGinity, J. W., Biomaterials. 2002, 23 (21), 4241-4248. 
 
3.1 ABSTRACT 
The thermal stability of polyethylene oxide (PEO) in sustained 
release tablets prepared by hot-melt extrusion was investigated.  The 
weight average molecular weight of the polymer was studied using gel 
permeation chromatography.  The chemical stability of PEO was found to 
be dependent on both the storage and processing temperature, and the 
molecular weight of the polymer.  Storage of the polymer above its 
melting point significantly increased polymer degradation, and the 
degradation process was accelerated as the molecular weight was 
reduced.  The thermal stability of PEO MW = 1,000,000 (PEO 1M) in 
sustained release chlorpheniramine maleate (CPM) tablets prepared by 
 71 
hot-melt extrusion was found to depend on the processing temperature 
and screw speed.  Lower molecular weight PEO MW = 100,000 (PEO 
100K) was demonstrated to be a suitable processing aid for PEO 1M.  
Incorporation of PEO 100K reduced degradation of PEO 1M and did not 
alter the release rate of CPM.  Vitamin E, Vitamin E Succinate and Vitamin 
E TPGS were found to be suitable stabilizers for PEO, however, ascorbic 
acid was shown to degrade the polymer in solution.  Thermal analysis 
demonstrated that Vitamin E Succinate and Vitamin E TPGS were 
dispersed at the molecular level in hot-melt extruded tablets.  Solubilized 
Vitamin E Succinate and Vitamin E TPGS suppressed the melting point of 
the polyethylene oxide.  Drug release rates from hot-melt extruded tablets 
stabilized with antioxidants were found to be dependent on the hydrophilic 
nature of the antioxidant. 
 
3.2 INTRODUCTION 
Hydrophilic polymers have been used extensively to prepare 
sustained and modified release drug delivery systems.  Several research 
groups have demonstrated the hot-melt extrusion technique [92] to be a 
viable method to prepare pharmaceutical dosage forms including granules 
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[2], pellets [3], sustained release tablets [5, 6] and transdermal drug 
delivery systems [10, 12, 14].   
 Dosage forms produced by the hot-melt extrusion method require a 
pharmaceutical grade thermoplastic material.  Polyethylene oxide (PEO) is 
a free flowing, thermoplastic homopolymer synthesized by the 
heterogeneous catalytic polymerization of ethylene oxide monomer.  It is 
commercially available in a wide range of molecular weights (100,000 to 
8,000,000).  PEO is miscible with water in all ratios due to hydration of 
the ether oxygen.  PEO is a semi-crystalline polymer with a melting range 
of 57 – 73ºC.   
PEO has been widely used to prepare sustained release dosage 
forms.  Studies have shown that the high molecular weight PEO 
successfully delayed the release rate of soluble and insoluble drugs from 
matrix tablets prepared by direct compression [93, 94].  Apicella and 
coworkers [95] used PEO to produce buccal adhesive etofylline films by 
solvent casting methods.  Stringer and Peppas [96] prepared cross-linked 
PEO hydrogels using gamma irradiation.  Efentakis and Vlachou [97] 
incorporated PEO as the rate-controlling carrier in sustained release 
gelatin capsules with both soluble and insoluble model drugs.  Zhang and 
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McGinity [5] investigated the drug release properties of sustained release 
tablets prepared by hot-melt extrusion techniques.   
Few studies have been reported in the literature concerning the 
stability of polymers in sustained release matrix tablets prepared by hot-
melt extrusion.  During hot-melt extrusion, polymers are subject to 
mechanical, thermal and oxidative degradation.  Mechanical degradation 
may be induced by the shear effects imposed by the rotating screw.  
Thermal de-polymerization results from high temperatures and includes 
random scission, scission from the ends of the polymer and unzipping of 
substitute groups.  Oxidative degradation is the result of a chemical 
reaction between oxygen molecules and the polymer.   
The objectives of the present study were to investigate the thermal 
stability of PEO (MW = 1,000,000 or PEO 1M) in sustained release 
chlorpheniramine maleate tablets prepared by the hot-melt extrusion 
process.  The influence of processing conditions on polymer stability was 
studied.  Low molecular weight PEO (MW = 100,000 or PEO 100K) was 
incorporated as a plasticizer to facilitate processing and antioxidants were 
included to stabilize the polymer.  The influence of processing parameters 
and incorporation of a plasticizer and antioxidants on the drug release 
properties of the tablet was also investigated.  Furthermore, the chemical 
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stability of PEO under accelerated storage conditions (40ºC, 60ºC and 
80ºC all at 75% relative humidity) was determined. 
 
3.3  MATERIALS AND METHODS 
3.3.1  Materials 
 
 Polyethylene oxide resins were purchased from Union Carbide Corp. 
(Danbury, CT) and Polysciences, Incorporated (Warrington, PA).  Vitamin 
E, Vitamin E acetate, Vitamin E Succinate, ascorbic acid, butylated 
hydroxyanisole, sodium perchlorate, triethylamine and chlorpheniramine 
maleate were purchased from Spectrum Chemical Co. (Gardena, CA).  
Vitamin E TPGS (D-a tocopheryl polyethylene glycol 1000 succinate) was 
supplied by Eastman Fine Chemicals (Kingsport, TN).  Methanol was 
purchased from EM Science (Gibbstown, NJ).  All materials were passed 
through a 20 mesh screen prior to use. 
3.3.2  Thermogravimetric Analysis 
Thermogravimetric analysis (TGA) was used to determine the 
thermal degradation temperature of the polymer.  A Perkin-Elmer 
(Norwalk, CT) 7-series Thermogravimetrical Analyzer was used in this 
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study.  Samples weighing approximately 20 mg were used for the 
analysis.  Nitrogen of ultrahigh purity was used as the purging gas for the 
furnace chamber.  The temperature ramp speed was set at 20ºC per 
minute, and the percentage weight loss of the samples was monitored 
from 30°C to 900°C. 
3.3.3  Molecular Weight Determination 
 Gel permeation chromatography was used to study the stability of 
the polymer by measuring its weight average molecular weight.  All 
standards and samples were prepared at 0.5% w/w concentrations in 
mobile phase under gentle agitation on a radial shaker (Aberbach Corp, 
Ann Arbor, MI) for 12 hours and injected immediately.  A Waters 
analytical system was used that included a WISP model 710B auto 
sampler (100mL sample injection volume), model 510 pump, 
UltrahydrogelÔ Columns (2000 and 1000 in series) and a model 410 
differential refractometer as the detector.  The data were collected using 
MillenniumÒ Version 3.2 software.  A third order calibration curve (R2 = 
0.99) was constructed using PEO standards (Polymer Standards Service, 
Silver Spring, MD) with peak molecular weights ranging from 4,450 to 
1,700,000.  The mobile phase was double-distilled water containing 0.1 M 
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sodium nitrate and was pumped at a flow rate of 0.8 ml/min.  The 
columns were held at an operating temperature of 35°C during analysis.  
Injection precision was found to have a relative standard deviation of 
1.5% for 10 injections. 
3.3.4  Differential Scanning Calorimetry Analysis 
 Differential Scanning Calorimetry (DSC) was used to characterize 
the thermal properties of the polymer, drug and antioxidants in physical 
mixtures and hot melt extrudates.  The DSC instrument was a model 2920 
from TA Instruments (New Castle, DE).  Ultrahigh purity nitrogen was 
used as the purge gas at a flow rate of 150 ml/min.  Approximately 10 mg 
of sample was weighed and sealed in aluminum pans.  The temperature 
ramp speed was 5°C per minute from 25°C to 150°C for all studies. 
3.3.5  Hot-melt Extrusion Process 
 Prior to each run, the system was purged with polyethylene for 10 
minutes followed by a 15 minute purge of PEO.  The drug, polymer(s) and 
or antioxidants were geometrically diluted and introduced into a Robot 
Coupe High Shear Blender (Model RS1 3VG, Jackson, MS) and mixed at 
2000 rpm for 3 minutes.  The resultant blend was fed into a single-screw 
Randcastle Extruder (Model RC 0750, Cedar Grove, NJ) equipped with a 
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Nitralloy 135M screw (3:1 compression ratio with flight configuration 
containing feed, compression and mixing sections) and a rod shaped die 
(6 mm in diameter).  The screw speed was either 10, 20, 40 or 60 rpm.  
The three heating zones and die temperatures were set and allowed to 
equilibrate.  The residence time of the materials in the extruder was 
approximately 2 – 3 minutes.  The extrudates were cooled to 45 – 55°C 
and manually cut into tablets weighing 250 mg.   
3.3.6  In Vitro Release Properties 
 Dissolution testing was performed according to apparatus II of USP 
24 on a Van Kel VK7000 Dissolution Tester (Van Kel Industries, Edison, NJ 
08820) equipped with an auto sampler (Model VK 8000).  The dissolution 
medium (900 ml of purified water) was maintained at 37°C (Model 750D) 
and agitated at 100 rpm.  Samples (5ml) were removed at specified time 
points over a 12 hour period. 
Samples were analyzed for CPM content using a Waters (Milford, 
MA) high performance liquid chromatography (HPLC) system with a 
photodiode array detector (Model 996) extracting at 261 nm.  Samples 
were pre-filtered through a 0.45 mm membrane (Gelman Laboratory, GHP 
Acrodisc).  A WISPÒ auto sampler (Model 710B) was used to inject 20mL 
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samples.  The data were collected and integrated using MillenniumÒ 
Version 3.2 software.  The column was a Waters mBondapakÔ C18 125Å 
(10 mm), 3.9  ´ 300 mm.  The mobile phase contained a mixture of 
methanol: water: triethylamine in volume ratios of 675:325:2.  The 
aqueous phase contained 0.71% w/w sodium perchlorate.   The solvents 
were vacuum filtered through a 0.45 mm nylon membrane and degassed 
by sonication.  The flow rate was 1.0 ml/min.  The retention time of the 
CPM was 9 minutes.  Linearity was demonstrated from 2 to 80 mg/ml (R2 
= 0.997) and injection repeatability was 0.38% Relative Standard 
Deviation (RSD) for 10 injections. 
 
3.4  RESULTS AND DISCUSSION 
3.4.1  The Thermal Stability of PEO 
The incorporation of oxygen into the backbone of an aliphatic chain 
polymer results in thermal instability since the C-O bond is less stable than 
a C-C bond [98].  When exposed to air or oxygen, PEO has been reported 
to oxidatively degrade in both bulk [99] and in solution [100].  This 
degradation has been reported to accelerate at elevated temperatures and 
upon exposure to ultraviolet light.  In the present study, the thermal 
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depolymerization temperature of PEO was measured by thermogravimetric 
analysis.  Depolymerization of polyethylene oxide was initiated at 
approximately 200°C.  The main product of the PEO depolymerization 
process is smaller polymer segments.   
The influence of storage temperature on the degradation of PEO 
1M as measured by changes in weight average molecular weight is 
presented in Figure 3.1.  The degradation rate of the polymer was faster 
under elevated storage temperatures.  PEO is a semicrystalline polymer, 
essentially a two phase material consisting of spherulitic crystals 
embedded in an amorphous continuum.  Maclaine and coworkers [101, 
102] reported the crystallinity of PEO of molecular weight 1,000,000 to be 
in the range of 45 – 55% using dilatometry.  Oxygen permeability of a 
polymer in the solid state increases with polymer chain mobility.  Due to 
the highly ordered structure of the crystalline spherulites, the oxygen 
diffusion rate is significantly lower in the crystalline region than in the 
amorphous region [103].   
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Figure 3.1:  Influence of storage temperature on the weight average 
molecular weight of Polyethylene Oxide (PEO Mw = 1,000,000) 
¨ 40°C · 60 °C  D 80°C 
Each point represents the mean ± standard deviation, n=3. 
 
 81 
 
When PEO was stored below its melting point (range 55 – 80°C) at 
40°C, or at 60°C, only the amorphous region and molten crystalline 
portions of the polymer are susceptible to oxidative degradation.  When 
stored above its melting temperature at 80°C, both the crystalline and 
amorphous regions of the polymer are completely molten and the 
oxidative degradation of PEO was substantially accelerated.  As polymer 
degradation accelerated, the physical appearance of the polymer changed, 
and when stored at 80°C for 14 days, PEO was soft and waxy with a 
distinctive odor.   
The thermal oxidation of PEO was highly dependent on polymer 
molecular weight.  The profiles in Figure 3.2 demonstrate that the lower 
molecular weight polymer degraded more rapidly than the higher 
molecular weight polymer (100,000 > 600,000 > 1,000,000).  Maclaine 
and coworkers [101] reported the crystallinity of PEO reached a maximum 
at molecular weight 6,000 and decreased with increasing molecular 
weight.  Because they are more crystalline, it was expected that low 
molecular weight polymer would be more resistant to thermal oxidation. 
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Figure 3.2:  Relationship of polymer molecular weight in the thermal 
stability of Polyethylene Oxide when stored at 60°C, 75% relative 
humidity. 
¨ 1,000,000, · 600,000 and D 200,000 
 Each point represents the mean ± standard deviation, n=3. 
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The melting point of a polymer crystal depends on its thickness, 
with smaller crystals melting at lower temperatures than larger crystals.  
Polymers are rarely crystallized to a uniform size and thus exhibit a 
melting range rather than a sharp melting point.  The manufacturing 
process can also influence crystal size if the cooling rate and time are not 
tightly controlled.   
Ozeki and coworkers [104] observed that the onset of melting and 
the melting point of PEO increased as the molecular weight increased.  
These results were confirmed in the present study.  The DSC scan of PEO 
(1M) in Figure 3.3 reveals a melting range from 55 to 80°C.  When stored 
at 60°C, smaller crystals that melt below 60°C are more susceptible to 
oxidative degradation.  Thus, it can be concluded from this study that a 
higher proportion of small crystals are present in the lower molecular 
weight PEO. 
 84 
 
38.27°C
134.98°C
d
c
b
a
70.42°C
77.01°C
-5
2
H
ea
t F
lo
w
 (
W
/g
)
20 40 60 80 100 120 140 160
Temperature (°C)Exo Up Universal V3.0G TA Instruments
 
Figure 3.3:  DSC profiles of the CPM, PEO and Antioxidants. 
(a) CPM, 
(b) Vitamin E Succinate 
(c) PEO (Mw = 1,000,000) 
(d) Vitamin E TPGS 
 85 
 
3.4.2  The Hot-melt extrusion stability of PEO 
The stability of PEO following hot-melt extrusion was investigated 
using a model formulation containing 20% chlorpheniramine maleate 
(CPM) and 80% PEO 1M.  The influence of hot-melt processing on the 
weight average molecular weight of three different lots of PEO 1M was 
investigated.  When extruded at 20 rpm and 70 – 105°C, the reduction in 
weight average molecular weight ranged from 8.2% to 11.3% for the 
three lots.  The differences from one lot to another were not statistically 
significant (n=6, a=0.05, p>0.10). 
The influence of extrusion conditions on the weight average 
molecular weight of PEO is presented in Figure 3.4.  At low screw speeds, 
polymer degradation increased with higher processing temperatures.  
These results suggest that thermal degradation rather than mechanical 
degradation was the dominant mechanism.  Processing temperature and 
the transit time through the extruder were the parameters that 
significantly influenced the extent of PEO degradation.  As screw speed 
was increased, polymer degradation decreased until melt fracture began 
to occur.  The melt behavior of PEO has been reported to be 
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pseudoplastic in nature [105].  As the screw speed increased, the melt 
viscosity decreased due to shear thinning and the transit time through the 
extruder decreased.  Melt fracture will occur when the polymer chains are 
forced to orient themselves in the die and recoil into a random 
configuration upon exit.  At very high screw speeds, polymer degradation 
was due to both mechanical and thermal degradation.   
Melt fracture was observed at the zone temperatures of 80, 90, 
110, 120°C and a screw speed of 60 rpm, and at zone temperatures of 85, 
100, 120 140°C and a screw speed of 80 rpm.  Melt fracture was not 
observed at the lower temperature settings due to drive overload.  These 
findings demonstrate that polymer stability can be modulated by process 
parameters and that high material throughput can be achieved.   
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Figure 3.4:  Influence of extrusion temperature & screw speed on the 
weight average molecular weight of PEO 1M (80% PEO 1M, 20% CPM). 
 
à 70,80,100,105°C; D 80,90,110,120°C; and o 85,100,120,140°C 
Each point represents the mean ± standard deviation, n=6. 
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Most extruders are supplied with an ammeter which indicates the 
load or current supplied by the drive motor to the screw in order to move 
the polymer through the extruder.  The influence of processing 
temperatures and screw speed on drive amperage is presented in Figure 
3.5.  The drive amperage follows the same trends as polymer degradation 
at all three processing temperatures.  At the processing conditions in 
which the polymer is more stable, the melt viscosity remained relatively 
high which created more resistance against the drive.  As the polymer 
degrades, lower molecular weight chains are formed, melt viscosity is 
reduced and the drive amperage decreases.  These findings demonstrate 
that drive amperage can be used as an indicator of polymer stability until 
melt fracture occurs.  At the point of melt fracture, drive amperage 
decreased due to increased chain scission, in addition to relaxation and 
uncoiling of the polymer at the die exit. 
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Figure 3.5:  Influence of processing temperature & screw speed on drive 
amperage. 
 
à 70,80,100,105°C; D 80,90,110,120°C; and o 85,100,120,140°C. 
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3.4.3  The Influence of Low Molecular Weight PEO 
Low molecular weight PEO (Mw = 100,000) was investigated as a 
processing aid for the model formulation containing PEO 1M and CPM.  
The presence of PEO 100K reduced the melt viscosity, friction and chain 
entanglements between the PEO 1M molecules.  As shown in Table 3.1, 
as the percentage of PEO 100K in the powder blend increased, the drive 
amperage decreased and the stability of PEO 1M increased.   
In formulations A and B, the two different PEO polymers eluted as 
a single peak.  However, formulation C, containing equal parts PEO 1M 
and PEO 100K eluted as two separate peaks.  In this formulation, the 
weight average molecular weight of the PEO 100K polymer increased 
following extrusion.  This demonstrates that degradation of PEO 1M 
during the extrusion process resulted in polymer chains with a weight 
average near 100,000.  Thus, the additional PEO 100K formed during 
processing was shown to plasticize the parent polymer.  This observation 
was confirmed by a reduction in drive amperage.    
The in vitro release properties of formulations A, B and C are 
presented in Figure 3.6.  The release rate of CPM from the extruded 
tablets was not significantly influenced by the presence of PEO 100K.  
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Although PEO 100K hydrates more rapidly and has a lower viscosity than 
PEO 1M, the rate of CPM diffusion through the swollen gel layer did not 
change substantially. 
CPM was found to be stable under the extrusion conditions studied.  
There was no change in HPLC retention time for the extruded samples 
and the drug was completely recovered in the dissolution media. 
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Table 3.1:  Extrusion Stability of PEO 1M and the Influence of PEO 100K on PEO Weight Average 
Molecular Weight as measured by Gel Permeation Chromatography. 
 
                    Formulation (%) 
           CPM    PEO 1M     PEO 100K 
Pre Extrusion 
MW (´ 106) 
Post Extrusion 
MW (´ 106) 
 
% Change 
Drive Current 
(Amps) 
A   20           70                10 1.050 ± 0.028 0.958 ± 0.024 -8.8 2.9 – 3.2 
B   20           60                20 0.912 ± 0.023 0.849 ± 0.025 -6.9 2.8 – 3.2 
1.135 ± 0.016 1.084 ± 0.018 -4.5 2.4 – 2.6 
C   20           40                40 
0.084 ± 0.005 0.093 ± 0.008 +10.7  
Unprocessed MW:  PEO (1M) MW = 1.188 ± 0.024 
 
Zone Temperatures: 70, 85, 100, 105°C 
Screw Speed: 20 rpm 
 
Values are reported as Average ± Standard Deviation, n=3. 
  93 
 
0
20
40
60
80
100
0 2 4 6 8 10 12
Time (hours)
P
er
ce
n
t 
C
P
M
 R
el
ea
se
d
 
Figure 3.6:  Influence of low molecular weight PEO on CPM release from 
hot-melt extruded tablets using USP Method II at 37°C and 100 rpm in 
900 ml purified water. 
¨ 20% CPM, 80% PEO 1M,  0% PEO 100K 
D 20% CPM, 70% PEO 1M, 10% PEO 100K  
à 20% CPM, 60% PEO 1M, 20% PEO 100K  
o 20% CPM, 40% PEO 1M, 40% PEO 100K 
 
Each point represents the mean ± standard deviation, n=6. 
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3.4.4  The Influence of Antioxidants 
The thermal oxidation of PEO in the solid state has been 
characterized as an autocatalytic free radical process [99].  Antioxidants 
are often used to hinder oxidation reactions by scavenging free radicals.  
Antioxidants that have been used in pharmaceutical preparations include 
Vitamin E and its derivatives, Vitamin C (ascorbic acid) and butylated 
hydroxyanisole (BHA).  Vitamin E TPGS is a water soluble derivative of 
natural Vitamin E.  It is ampipathic and hydrophilic with surface active 
properties and has been used as an emulsifier, solubilizer and absorption 
enhancer.  The influence of antioxidants on the hot-melt extrusion stability 
of PEO 1M matrix tablets containing CPM is presented in Table 3.2.  The 
addition of 5% Vitamin E succinate, 1% Vitamin E and 30% Vitamin E 
TPGS successfully retarded molecular weight loss of PEO.  The color of the 
extrudates was unchanged.  These compounds have previously been 
found to suppress free radical production in photoirradiated pheolmelanin 
[106].  In contrast, Vitamin C and BHA did not stabilize PEO. 
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Table 3.2:  Extrusion Stability of PEO 1M and the Influence of Antioxidants 
on PEO Weight Average Molecular Weight as measured by Gel Permeation 
Chromatography. 
(20% CPM, 80 – x% PEO 1M and x% Antioxidant) 
 
Formulation 
Post Extrusion 
MW (´ 106) 
 
% Change 
Drive Current 
(Amps) 
No Antioxidant 0.836 ± 0.008 - 11.3 3.0 – 3.4 
0.5% Vitamin E Succinate 0.828 ± 0.005 - 12.1 3.0 – 3.3 
1.0% Vitamin E Succinate 0.867 ± 0.014 - 8.0 2.8 – 3.4 
5.0% Vitamin E Succinate 0.917 ± 0.019 - 2.7 2.7 – 3.1 
1.0% Vitamin E Acetate 0.828 ± 0.012 - 12.1 4.3 – 4.9 
5.0% Vitamin E Acetate 0.826 ± 0.039 - 12.3 6.5 – 7.0 
1.0% Vitamin E 0.916 ± 0.027 - 2.8 3.7 – 4.1 
15.0% Vitamin E TPGS 0.843 ± 0.025 - 10.5 2.7 – 3.4 
30.0% Vitamin E TPGS 0.907 ± 0.026 - 3.7 2.6 – 2.9 
0.5% Ascorbic acid 0.730 ± 0.102 - 22.5 3.0 – 3.3 
1.0% Ascorbic acid 0.626 ± 0.076 - 33.5 4.5 – 5.0 
0.5% BHA 0.864 ± 0.013 - 8.3 3.4 – 3.7 
1.0% BHA 0.874 ± 0.009 - 7.2 3.7 – 4.3 
Unextruded PEO MW 0.942 ± 0.021 
 
Zone Temperatures: 70, 85, 100, 105°C 
Screw Speed: 20 rpm 
Molecular weight values are reported as the mean ± standard deviation, n =3. 
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Both Vitamin E succinate and Vitamin E TPGS decreased the torque 
during extrusion suggesting an improvement in polymer chain motion.  
The miscibility of Vitamin E Succinate and Vitamin E TPGS in PEO was 
studied by DSC (Figure 3.7).  The melting points of CPM, PEO 1M, Vitamin 
E TPGS and Vitamin E Succinate were found to be 135°C, 70°C, 38°C and 
77°C, respectively.  The melting point of Vitamin E TPGS can be observed 
in the thermograms of the physical mixtures.   Thermograms of the 
extrudates containing Vitamin E succinate, 15% Vitamin E TPGS and 30% 
Vitamin E TPGS demonstrate a decrease in the melting point of PEO of 
approximately 9°C, 9°C and 10°C, respectively.  Thermal transitions 
corresponding to the melting points of Vitamin E succinate and Vitamin E 
TPGS were not observed in the extrudates.  These results demonstrate 
that both Vitamin E succinate and Vitamin E TPGS were miscible with PEO 
in the melt and when incorporated into the PEO crystals, the Vitamin E 
derivatives did not recrystallize after the extrudate cooled.     
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Figure 3.7:  DSC profiles of the Physical Mixtures and Extruded Tablets. 
 
(e) Physical mixture of 20% CPM, 75% PEO and 5% Vitamin E Succinate 
(f) Hot-melt extrudate of 20% CPM, 75% PEO and 5% Vitamin E 
Succinate  
(g) Physical mixture of 20% CPM, 65% PEO and 15% Vitamin E TPGS  
(h) Hot-melt extrudate of 20% CPM, 65% PEO and 15% Vitamin E TPGS  
(i) Physical mixture of 20% CPM, 50% PEO and 30% Vitamin E TPGS  
(j) Hot-melt extrudate of 20% CPM, 50% PEO and 30% Vitamin E TPGS. 
 98 
Both butylated hydroxyanisole and Vitamin E acetate were 
ineffective in stabilizing the molecular weight of PEO during extrusion.   
The torque during extrusion was significantly increased.  It was 
anticipated that the oily nature of Vitamin E acetate would function as a 
thermal lubricant during the extrusion process.  In general, suitable 
solvents for polymers will chemically and physically resemble the 
structural repeat units of the polymer.  If this situation exists, the 
adhesive forces between the solvent and polymer are similar to the 
cohesive forces between solvent molecules or between polymer 
molecules.  An exchange of a solvent molecule by a polymer structural 
unit occurs with little change in the adhesive and cohesive forces.  In the 
case of poor or unsuitable solvents, the cohesive forces between polymer 
molecules are more favorable.  If this situation exists, the polymer chain 
reduces its hydrodynamic radius. 
Other researchers have reported that the acetate anion caused PEO 
to salt out of aqueous solution [105].  The results of our study suggested 
that the residual acetate anions in Vitamin E acetate reduced the polymer 
radius in the molten state, increasing chain entanglements and 
consequently, the load required to move the polymer through the 
extruder. 
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 The appearance of extrudates containing ascorbic acid changed 
from white to brown within two hours.  After extrusion, the molecular 
weight of PEO was considerably reduced and the polydispersity increased.  
McGary reported that strong acids reduced the solution viscosity of PEO 
[100].  Solutions of unprocessed PEO and ascorbic acid were prepared to 
examine whether the reduction in PEO molecular weight was the result of 
the extrusion process or a solution phenomenon (Table 3.3).  The results 
from the solution study demonstrate that small quantities of ascorbic acid 
significantly reduced PEO molecular weight by an acid catalyzed chain 
scission reaction.  However, it is also possible that the PEO degradation in 
solution with ascorbic acid is also accelerated by conditions during GPC 
analysis.  It has been reported that ascorbic acid solutions undergo 
oxidation in the presence of air and are catalyzed by heat and traces of 
copper and iron [107]. 
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Table 3.3:  Influence of Ascorbic Acid on the Solution Stability of 
Polyethylene Oxide 1M as measured by Gel Permeation Chromatography. 
 
 
Formulation % (w/w) 
   
          PEO       Ascorbic Acid MW (´ 106) % Change 
100.0 0 1.241 ± 0.008  
99.9 0.10 1.119 ± 0.016 - 3.4 
99.5 0.50 0.921 ± 0.038 - 25.8 
99.0 1.00 0.788 ± 0.030 - 36.8 
98.0 2.00 0.587 ± 0.019 - 52.8 
 
Samples stored at 25°C for 12 hours. 
Molecular weight values are reported as mean  ± standard deviation, n=3. 
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The influence of the antioxidants on the release of CPM from 
extruded tablets and tablets prepared by direct compression is displayed 
in Figure 3.8.  All extruded formulations displayed comparable release 
rates.  The release of CPM from tablets prepared by direct compression 
was more rapid than those prepared by hot-melt extrusion due to the 
increase in porosity and a decrease in tortuosity in the tablet compact.  
The formulation containing 30% Vitamin E TPGS released CPM more 
rapidly than the other formulations.  Vitamin E TPGS is amphiphillic and 
can influence the release rate of CPM in two ways.  Although the waxy, 
hydrophobic portion of the molecule can hinder the penetration of water 
into the tablet core, the hydrophilic portion of the molecule can reduce the 
gel strength of the PEO matrix and increase erosion during dissolution.  In 
this case, the latter is the dominant factor.  The formulation containing 
1% Vitamin E released CPM more slowly than all other formulations.  The 
hydrophobic nature of Vitamin E delayed the penetration of water into the 
PEO matrix, resulting in a slower rate of gel hydration and formation. 
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Figure 3.8:  Influence of antioxidants on the release of CPM from tablets 
using USP Method II at 37°C and 100 rpm in 900 ml purified water. 
à  20% CPM, 80% PEO 1M, Direct Compression  
o  20% CPM, 50% PEO 1M, 30% Vitamin E TPGS Extrudate 
¨  20% CPM, 75% PEO 1M, 5% Vitamin E Succinate Extrudate 
D  20% CPM, 80% PEO 1M Extrudate 
X  20% CPM, 79% PEO 1M, 1% Vitamin E Extrudate 
 
Each point represents the mean ± standard deviation, n=6. 
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3.5  CONCLUSIONS 
The results of this study demonstrated that the thermal stability of 
PEO was dependent on both the storage temperature and the molecular 
weight of the polymer.  Storage of the polymer above its melting point 
significantly increased its degradation.  Polymer degradation when stored 
below its melting point is due to oxygen permeation in the amorphous 
region of the polymer. 
PEO matrix tablets prepared by hot-melt extrusion were sensitive to 
both process temperature and screw speed.  The mechanism of polymer 
degradation during extrusion is both thermal and mechanical.  At very 
high screw speeds, degradation is due to melt fracture.  The amperage 
consumed by the extruder motor drive can be used as an indicator of 
polymer stability.   
The addition of PEO 100K improved processing of PEO 1M and did 
not significantly influence the rate of CPM release from matrix tablets.  
Vitamin E, Vitamin E succinate and Vitamin E TPGS were found to be 
suitable stabilizers for PEO during processing.  Vitamin E succinate and 
Vitamin E TPGS were dispersed at the molecular level in hot-melt extruded 
tablets.  Ascorbic acid was shown to degrade the polymer in solution.  
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Drug release rates from hot-melt extruded tablets stabilized with 
antioxidants were dependent on the hydrophilic nature of the antioxidant. 
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CHAPTER 4  CHARACTERIZATION OF THE 
PHYSICOCHEMICAL PROPERTIES AND MECHANISM 
OF DRUG RELEASE FROM ETHYL CELLULOSE 
MATRIX TABLETS PREPARED BY DIRECT 
COMPRESSION AND HOT-MELT EXTRUSION 
 
4.1  ABSTRACT 
The objective of this research project was to determine the 
physicochemical properties and investigate the drug release mechanism 
from ethyl cellulose matrix tablets prepared by either direct compression 
or hot-melt extrusion of binary mixtures of water soluble drug 
(guaifenesin) and the polymer.  Ethyl cellulose was separated into “fine” 
or “coarse” particle size fractions corresponding to 325 - 80 mesh and 80 - 
30 mesh particles, respectively.  Tablets containing 30% guaifenesin were 
prepared at 10 kN, 30 kN, or 50 kN compaction forces and extruded at 
processing temperatures of 80 – 90°C and 90 – 110°C.  The drug 
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dissolution and release kinetics were determined and the tablet pore 
characteristics, tortuosity, thermal properties and surface morphologies 
were studied using helium pycnometry, mercury porosimetry, differential 
scanning calorimetry and scanning electron microscopy.  The tortuosity 
was measured directly by a novel technique that allows for the calculation 
of diffusion coefficients in 3 experiments.  The Higuchi diffusion model, 
percolation theory and polymer free volume theory were applied to the 
dissolution data to explain the release properties of drug from the matrix 
systems. The release rate was shown to be dependent on the ethyl 
cellulose particle size, compaction force and extrusion temperature. 
 
4.2  INTRODUCTION 
Ethyl cellulose (EC) is a nontoxic, stable, compressible, inert, 
hydrophobic polymer that has been widely used to prepare 
pharmaceutical dosage forms.  The properties of ethyl cellulose sustained 
release products including film coated tablets [108], microspheres [109, 
110], microcapsules [111] and matrix tablets for both soluble and poorly 
soluble drugs [112, 113] have been reported.   
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Hot-melt extrusion (HME) is a widely used process in the plastics 
industry to produce tubing, pipes and films.  In pharmaceutical systems, 
HME has been used to prepare granules, sustained-release tablets, and 
transdermal drug delivery systems [3, 5, 6, 114, 115].  It has been 
demonstrated that the processing method can dictate the porosity and 
pore structure of the dosage form [116, 117].  Previous workers have also 
shown that thermal processing results in a more tortuous product [118, 
119]. 
Several researchers have suggested that diffusion controlled sustained 
release dosage forms prepared by HME have slower drug release rates 
than those prepared by traditional methods due to lower porosity and 
higher tortuosity [4].  Polymeric materials are softened or molten during 
hot-melt extrusion and subjected to intense mixing resulting in the 
generation of high pressures.  Air present in the powder bed can be 
excluded from the polymer melt during hot-melt extrusion.  As a result, 
HME dosage forms are expected to have a lower porosity and higher 
tortuosity, in comparison with the dosage forms prepared by tabletting 
processes.  
The Higuchi Square Root Model [120] has been successfully applied to 
model the kinetics of drug release from matrix systems.  The equation 
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(4.1) was derived from Fick’s Law of Diffusion and applied to porous 
hydrophobic polymeric drug delivery systems in homogenous matrices and 
granular matrices.   
tktCCCDtCCCDtQ aoaappaoas =-=-= )2()2()( ee
t
e       (Equation 4.1) 
In equation 4.1, Q(t) represents the cumulative amount of drug released 
at time t per unit surface area, Ds denotes the drug diffusion coefficient in 
the release medium, Co is the total amount of drug in the matrix, Ca is the 
solubility of the drug in the release media, e is the porosity, t is the 
tortuosity of the matrix, Dapp is the apparent or observed diffusion 
coefficient (
t
eDs
appD = ) and k is the dissolution rate constant.  Drug 
release can be manipulated by varying: (a) the initial concentration of 
drug within matrix; (b) porosity; (c) tortuosity; (d) polymer system 
forming the matrix; and (e) the solubility of the drug. 
 Drug release from a porous, hydrophobic polymeric drug delivery 
system occurs when the drug comes into contact with the dissolution 
media, subsequently dissolves and diffuses through media filled pores.  
Thus, geometry and structure of the pore network are important in this 
process [121, 122].  The Higuchi model has been reported to fail at drug 
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loading levels below the percolation threshold [6].  Below the percolation 
threshold, incomplete drug release is observed presumably due to limited 
accessibility of many drug particles to the dissolution medium since they 
are encapsulated by water insoluble polymeric materials. 
 The objectives of the present study were to determine the 
physicochemical properties of ethyl cellulose matrix tablets prepared by 
either direct compression or hot-melt extrusion in order to explain the 
drug release mechanism.  The influence of compaction force and 
processing temperature on drug release rates and the physical properties 
of the tablets was studied.  The effect of ethyl cellulose particle size was 
examined in tablets prepared by both direct compression and hot-melt 
extrusion.  The median pore size, porosity and tortuosity of the matrix 
tablets prepared by the two techniques were determined using the Webb 
technique allowing calculation of the diffusion coefficients.   
 
4.3  THE THEORY OF MERCURY INTRUSION POROSIMETRY AND 
TORTUOSITY 
Knowledge of tortuosity is necessary to determine diffusion coefficients 
from observed dissolution data.  Researchers have relied upon secondary 
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methods to determine tortuosity.  These techniques required several steps 
and were time intensive.  Recently, a novel approach using mercury 
intrusion porosimetry for direct measurement of tortuosity was reported 
[123].  Mercury intrusion porosimetry has been used to study the pore 
characteristics of tablets [116, 124, 125], granules [117, 126], ceramic 
particles for sustained drug delivery [127] and excipients [128].  The 
technique is based upon the unique properties of mercury.  Mercury 
behaves as a non-wetting liquid toward most substances and will not 
penetrate a solid unless pressure is applied.  For circular pore openings, 
the Washburn equation (4.2) [129] relates the applied pressure, P, and 
the radius, r, of the pores intruded with a non-wetting liquid: 
P
r
qg cos2-
=      (Equation 4.2) 
where g is the surface tension of mercury and q is the contact angle 
between the liquid and sample.  The inverse relationship between pore 
radius and applied pressure indicates low pressures are used to measure 
large pore sizes and high pressures are used to measure small pore sizes. 
Katz & Thompson [130, 131] introduced an expression (4.3) for 
determination of permeability in porous rocks from mercury intrusion 
curves based upon concepts from Percolation Theory [132, 133].  These 
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researchers found that absolute permeability, K, was related to the rock 
conductivity at a characteristic length Lc.   
)(
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=      (Equation 4.3) 
Equation 4.3 requires determination of the length at which 
conductance is at a maximum, Lmax, and the fraction of total porosity, f, 
filled at this length S(Lmax).  The characteristic length, Lc, is the length at 
which mercury spans the entire sample and was found to be the point at 
which percolation begins.  It is determined at the point of inflection in the 
rapidly rising region of the cumulative intrusion curve.  Several different 
scientific disciplines have used the Katz-Thompson method to determine 
permeability in a variety of materials [134-138]. 
Jörgen Hager also derived an expression for material permeability 
based upon a capillary bundle model and knowledge of material tortuosity 
[139].  The capillary bundle model describes the pore network as 
homogenously distributed in random directions.  Using the Hagen-
Poiseuille correlation for fluid flow in cylindrical geometries in combination 
with Darcy’s Law, Hager was able to derive an equation (4.4) for 
permeability, K in terms of total pore volume, Vtot, material density, r, 
 112
pore volume distribution by pore size,ò
=
=
max,
min,
)(2
c
c
r
r v
df
h
h
hhh  and material 
tortuosity, t.  In this method, Hager obtained all parameters except 
tortuosity from mercury intrusion porosimetry analysis. 
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Webb concluded that combining the Hager and Katz-Thompson 
expressions (equation 4.5) provided a means for determining tortuosity 
from mercury intrusion porosimetry data [123, 140].   
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Since the determination of tortuosity depends upon permeability, changes 
in material permeability during the analysis will affect the reported value 
for tortuosity.  Webb also reported that improved accuracy was achieved 
using true density data from helium pycnometry.  Thus, the Webb 
technique allows determination of tortuosity from only two experiments, 
helium pycnometry and mercury intrusion.  The apparent diffusion 
coefficient and diffusion coefficient can then be calculated using the rate 
constant from dissolution studies. 
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4.4  MATERIALS AND METHODS 
4.4.1  Materials 
Guaifenesin and Glacial Acetic Acid were purchased from Spectrum 
Laboratory Products (Gardenia, CA).  Ethyl cellulose grade S10 was kindly 
donated by the Dow Chemical Company (Midland, MI).  Methanol was 
purchased from EM Science (Gibbstown, NJ). 
4.4.2  Methods 
4.4.2.1  Preparation of Tablets 
Ethyl cellulose was sieved into two fractions.  The “coarse” fraction 
included the material that passed through a 30 mesh screen and was 
retained by an 80 mesh screen.  The “fine” fraction included material that 
passed through 80 mesh screen and was retained on a 325 mesh screen.  
Guaifenesin was passed through a 30 mesh screen prior to use.  The ethyl 
cellulose particle size fractions were confirmed by laser light scattering 
using a Malvern Mastersizer S (Malvern Instruments Limited, Malvern, 
Worcestershire, UK).   
A model formulation containing 30% guaifenesin and 70% ethyl 
cellulose was selected for this study.  The drug and polymer were 
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geometrically diluted in a glass mortar and pestle and then introduced into 
a V Blender (Blend MasterÒ,Patterson-Kelley, East Stroudsburg, PA) and 
mixed for 15 minutes.  Tablets were prepared from the resultant blend by 
either direct compression or via hot-melt extrusion.    
4.4.2.2  Direct Compression Process 
Tablet compacts were prepared using a Carver 25 ton laboratory 
press (Fred Carver, Menomonee Falls, WI) and a 6 mm diameter flat faced 
punch and die set.  The force applied on the punches was measured using 
a load cell (ISI Inc., Round Rock, TX) mounted directly on the press with 
strain gauge sensors.  Tablets weighing 250 ± 5 mg were compressed to 
10 kN, 30 kN or 50 kN for 3 seconds and ejected from the die. 
4.4.2.3  Hot-Melt Extrusion Process 
The powder blend was fed into a single-screw Randcastle Extruder 
(Model RC 0750, Cedar Grove, NJ) equipped with a Nitralloy 135M screw 
(3:1 compression ratio with flight configuration containing feed, 
compression and mixing sections) and a rod shaped die (6 mm in 
diameter).  The screw speed was 20 rpm.  The three heating zones and 
die temperatures were set and allowed to equilibrate.  Extrusion samples 
were prepared using two different processing temperature ranges: “low” 
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(80, 85, 85, 90°C) and “high” (90, 105, 105, 110°C).  The residence time 
of the materials in the extruder was approximately 2 – 3 minutes.  The 
extrudates were cooled to 45 – 55 °C and manually cut into tablets 
weighing 250 ± 5 mg.   
4.4.2.4  In Vitro Release Properties 
 Dissolution testing was performed using apparatus II on a Van Kel 
VK7000 Dissolution Tester (Van Kel Industries, Edison, NJ 08820) 
equipped with an auto sampler (Model VK 8000) according to the 
guaifenesin tablet monograph in USP 24.  Six tablets were placed into the 
dissolution medium (900 ml of purified water) which was maintained at 
37°C by a circulating bath (Van Kel Model 750D) and agitated at 50 rpm.  
Samples (5ml) were removed at specified time points over a 12 hour 
period without media replacement. 
Samples were analyzed for guaifenesin content using a Waters 
(Milford, MA) high performance liquid chromatography (HPLC) system 
with a photodiode array detector (Model 996) extracting at 276 nm.  
Samples were pre-filtered through a 0.45 mm membrane (Gelman 
Laboratory, GHP Acrodisc).  An auto sampler (Model 717plus) was used to 
inject 20mL samples.  The data were collected and integrated using 
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EmpowerÒ Version 5.0 software.  The column was an Alltech AlltimaÔ C18 
3 mm, 150 ´ 4.6 mm.  The mobile phase contained a mixture of 
water:methanol:glacial acetic acid in volume ratios of 600:400:15.  The 
solvents were vacuum filtered through a 0.45 mm nylon membrane and 
degassed by sonication.  The flow rate was 1.0 ml/min.  The retention 
time of the guaifenesin was 4 minutes.  Linearity was demonstrated from 
2 to 200 mg/ml (R2 = 0.997) and injection repeatability was 0.35% relative 
standard deviation for 10 injections. 
4.4.2.5  True Density by Helium Pycnometry 
The true density of the powder formulations and tablets was 
determined in triplicate using helium pycnometry (MicrometricsÒ AccuPyc 
1330 Pycnometer; Norcross, GA).  Twelve tablets were placed in a 12 cm3 
sample cup and purged twenty times at 19.85 psi followed by six 
analytical runs at 19.85 psi.  The equilibration rate was 0.0050 psi/minute.  
An equivalent mass of the powder mixtures was measured in the same 
manner. 
4.4.2.6  Mercury Intrusion Porosimetry 
The bulk density and tortuosity of the tablets were determined 
using an Autopore IV 9500 mercury intrusion porosimeter (Micromeritics, 
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Norcross, GA).  Incremental volumes of mercury were plotted against pore 
diameters according to the Washburn equation (4.2).  A surface tension 
value of 485 dynes/cm was used for mercury and its contact angle was 
130°.  Twelve tablets were placed in #5 bulb penetrometer and pressure 
was applied from 1 to 15,000 psia, representing pore diameters of 0.012 – 
360 mm.  The pressure at each point was allowed to equilibrate for 10 
seconds.  Each run was performed in triplicate.  Tablets were analyzed 
prior to and post dissolution, with the removal of water from the tablets 
following dissolution by drying to a constant weight under vacuum for a 
minimum of 72 hours.   
4.4.2.7  Percent Effective Porosity Determination 
Percent effective porosity, e was determined according to the 
Varner technique [141] using equation (4.6) in which rt is the true density 
of the tablet as determined by helium pycnometry and rb is the bulk 
density as determined by mercury intrusion porosimetry.  Three runs of 
twelve tablets were analyzed first by helium pycnometry followed by 
mercury intrusion porosimetry.    
b
bt
r
rr
e
-
=      (Equation 4.6) 
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4.4.2.8  Modulated Differential Scanning Calorimetry Analysis 
 Temperature modulated differential scanning calorimetry (M-DSC) 
was used to characterize the thermal properties of the polymer and drug 
in physical mixtures and hot melt extrudates.  M-DSC analysis was 
conducted using a Thermal Advantage Model 2920 from TA Instruments 
(New Castle, DE) equipped with Universal Analysis 2000 software.  
Ultrahigh purity nitrogen was used as the purge gas at a flow rate of 150 
ml/min.  The sample was weighed to 10 ± 5 mg and placed in aluminum 
pans (Kit 0219-0041, Perkin-Elmer Instruments, Norwalk, CT) and crimped 
with an aluminum lid.  The temperature ramp speed was 2°C per minute 
from 25°C to 150°C for all studies with a modulation rate of 1.592°C every 
minute. 
4.4.2.9  Scanning Electron Microscopy 
Scanning electron microscopy was used to study the surface 
morphology of the hot-melt extruded tablets.  The samples were mounted 
on an aluminum stage using adhesive carbon tape and placed in a low 
humidity chamber for 12 hours prior to analysis.  Samples were coated 
with gold-palladium for 60 seconds under an argon atmosphere using a 
Pelco® Model 3 Sputter Coater (TED Pella, Inc., Tusin, CA, USA) in a high 
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vacuum evaporator equipped with an omni-rotary stage tray.  Scanning 
electron microscopy was performed using a Hitachi S-4500 field emission 
microscope operating at an accelerating voltage of 15 kV and a 15 mA 
emission current.  Images were captured with QuartzÒ software. 
4.4.2.10  Statistical Analysis 
One-way analysis of variance (ANOVA) was used to determine 
statistically significant differences between results.  Results with p values 
< 0.05 were considered statistically significant (a = 0.05).  Dissolution 
curves were analyzed by the model independent approach of Moore and 
Flanner for dissolution curve comparison using the similarity (f1) and 
difference factors (f2) [142]. 
 
4.5  RESULTS & DISCUSSION 
4.5.1  The Influence of Ethyl Cellulose Particle Size on Drug 
Release 
The influence of ethyl cellulose particle size and processing 
conditions on the release rate of guaifenesin from matrix tablets was 
studied.  The influence of ethyl cellulose particle size, compaction force 
and extrusion temperature on guaifenesin release rate is presented in 
 120
Figure 4.1 and Figure 4.2.  The guaifenesin release rate from the matrix 
was highly dependent upon ethyl cellulose particle size and the processing 
conditions employed to prepare the tablet.  In both cases, slower release 
rates were observed with small particle size ethyl cellulose.   
According to Percolation Theory, when a matrix is composed of a 
water soluble drug and a water insoluble polymer, drug release occurs by 
dissolution of the active ingredient through capillaries composed of 
interconnecting drug particle clusters and the pore network [143, 144].  
As drug release continues, the interconnecting clusters increase the pore 
network through which interior drug clusters can diffuse.  The total 
number of ethyl cellulose particles increases when its particle size is 
reduced.  With more ethyl cellulose particles present, the theory predicts 
that fewer clusters of soluble drug substance are formed.  Furthermore, 
the presence of finite drug clusters (encapsulated drug particles) is more 
statistically plausible.  The resulting pore network becomes less extensive 
and more tortuous resulting in slower drug release.   
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Figure 4.1:  Influence of ethyl cellulose particle size, compaction force 
and extrusion temperature on guaifenesin release from matrix tablets 
prepared by direct compression and hot-melt extrusion. 
   
Matrix Tablets Prepared Using “Fine” Ethyl Cellulose (325 – 80 Mesh) 
 
o Direct Compression, 10 kN 
à Direct Compression, 30 kN 
D Direct Compression, 50 kN 
· Hot-Melt Extrusion, 80, 85, 85, 90°C 
¨ Hot-Melt Extrusion, 90, 105, 105, 110°C 
 
Each point represents the mean ± standard deviation, n = 6. 
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Figure 4.2:  Influence of ethyl cellulose particle size, compaction force 
and extrusion temperature on guaifenesin release from matrix tablets 
prepared by direct compression and hot-melt extrusion.   
 
Matrix Tablets Prepared Using “Coarse” Ethyl Cellulose (80 – 30 Mesh) 
o Direct Compression, 10 kN 
à Direct Compression, 30 kN 
D Direct Compression, 50 kN 
· Hot-Melt Extrusion, 80, 85, 85, 90°C 
¨ Hot-Melt Extrusion, 90, 105, 105, 110°C 
 
Each point represents the mean ± standard deviation, n = 6. 
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Mercury porosimetry and helium pycnometry were used to 
determine the pore characteristics and tortuosity of the tablets prior to 
dissolution testing.  The median pore radius, percent effective porosity 
and tortuosity of the matrix tablets are presented in Table 1.  Statistically 
significant differences in median pore radius (n = 3, p <0.006), porosity 
(n = 3, p <0.02) and tortuosity (n = 3, p <0.009) were observed between 
matrix tablets prepared with “fine” and “coarse” ethyl cellulose particle 
sizes.  The median pore radius was smaller, the tablets less porous and 
more tortuous when prepared with “fine” ethyl cellulose (137 – to 529 Å, 
0.4 – 4.1% porosity and 4.7 – 321 tortuosity) than in tablets prepared 
with “coarse” ethyl cellulose (351 to 1439 Å, 0.7 to 6.5% porosity and 1.3 
– 125 tortuosity).  These data are supported by the dissolution results. 
Katikaneni and coworkers [145-148] reported that 
pseudoephedrine hydrochloride release from ethyl cellulose matrix tablets 
prepared by direct compression was controlled by ethyl cellulose particle 
size and compression force.  These authors concluded that the drug 
release rate decreased due to a reduction in porosity and increased matrix 
tortuosity at high compaction forces or when a finer particle of size ethyl 
cellulose was used.  The findings in the present study confirm the work of 
Katikaneni, support the predictions of Percolation Theory and demonstrate 
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the utility of the mercury porosimetry technique for determination of 
tortuosity. 
Generally, pore radii greater than 200 Å are necessary to avoid 
hindered diffusion [149].  Hindered diffusion can be due to steric 
exclusion or hindered particle motion.  In these situations, either the pore 
radii are sufficiently small that the molecular dimensions of the solute 
restrict its diffusion or excessive frictional resistance is created.  Hindered 
diffusion is typically observed when values of the particle radius to pore 
wall radius ratio are greater than 0.1.  The molecular dimensions of 
guaifenesin were modeled using SAVOL3 software to assess the likelihood 
of hindered diffusion (Figure 4.3) [150].  Assuming a spherical shape, 
guaifenesin was found to have a radius of 3.53 Å excluding a solvent 
radius and 5.44 Å with a solvent radius.  Assuming an ovoid shape and 
including a solvent radius, the model predicted the major axis to be 7.84 
Å, the first minor axis to be 6.13 Å and the second minor axis to be 3.89 
Å.  Thus, the minimum guaifenesin particle radius to pore radius ratio is 
0.04 in the case of the hot-melt extruded tablets prepared using “fine” 
ethyl cellulose and processed at 90 – 110°C.  This value is sufficiently 
small that hindered diffusion can be considered negligible. 
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Figure 4.3:  3-Dimensional image of the molecular dimensions of Guaifenesin using SAVOL3 software.
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Table 4.1:  Median pore radius, % porosity and tortuosity of matrix tablets prepared by direct 
compression (DC) and hot-melt extrusion (HME) containing 30% guaifenesin and 70% ethyl cellulose 
measured before and after dissolution testing.   
Median Pore Radius (Å) % Porosity Tortuosity Processing Conditions 
Before After Before After Before After 
“Fine” Ethyl Cellulose (325 – 80 mesh) 
DC 10 KN 529 ± 24  4.1 ± 0.3  4.7 ± 1.1  
DC 30 KN 476 ± 26  3.8 ± 0.2  6.0 ± 0.6  
DC 50 KN 475 ± 17  3.1 ± 0.2  6.9 ± 0.9  
HME 80, 85, 85, 90°C 264 ± 8 575 ± 51 1.0 ± 0.2 8.1 ± 1.8 53.2 ± 8.1 4.7 ± 0.6 
HME 90, 105, 105, 110°C 137 ± 6 521 ± 65 0.4 ± 0.2 7.8 ± 2.2 321 ± 22 5.2 ± 0.9 
“Coarse” Ethyl Cellulose (80 – 30 mesh) 
DC 10 KN 1439 ± 42  6.5 ± 0.2  1.3 ±  0.7  
DC 30 KN 906 ± 23  5.7 ± 0.3  2.1 ± 0.6  
DC 50 KN 710 ± 25  5.2 ± 0.2  2.8 ± 0.5  
HME 80, 85, 85, 90°C 392 ± 11 642 ± 48 2.3 ± 0.4 8.7 ± 1.4 41.8 ± 5.5 4.4 ± 0.3 
HME 90, 105, 105, 110°C 351 ± 13 588 ± 57 0.7 ± 0.1 8.0 ± 1.1 125 ± 16 5.0 ± 1.1 
Each point represents the mean ± standard deviation, n = 3. 
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Several assumptions are made using the mercury porosimetry 
technique which can introduce considerable error into the measurements.  
The assumption of circular pore cross sections or “cylindrical pore 
geometry” is due to mathematical convenience in order to avoid 
complexities calculating mean radii and contact angles in irregularly 
shaped pores.  As a result, the technique is biased to calculate smaller 
pore sizes than are actually present.  Furthermore, “ink bottle pores” also 
bias the pore size calculation to the small side.  Ink bottle pores are 
defined as pores in which the diameter increases as one moves to its 
inner dimensions [151, 152].  Mercury intrusion also involves subjecting 
the tablets to equal pressures from 360° as the mercury is forced inside.  
This means that as mercury intrudes into the pores, the walls of pores 
penetrated by mercury at a given pressure are uniformly affected by the 
same pressure.  This makes collapse of a pore wall unlikely.  However, the 
tablet can compress under the applied pressure which allows for 
additional mercury to intrude.  This also biases measurement to 
calculation of smaller than actual pore size.  Obviously, the compression of 
ethyl cellulose is a concern using this technique.  To minimize the impact 
of tablet compression, the applied pressure was not allowed to exceed 
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that applied during the direct compression experiments (50 kN or 15,000 
psia).  Despite these limitations, pore size information obtained from 
mercury porosimetry experiments has been consistently demonstrated to 
be representative. 
4.5.2  The Influence of Tableting Technique on Drug Release  
Guaifenesin release rates were considerably slower in tablets 
prepared by hot-melt extrusion than those prepared by direct compression 
as shown in Figure 4.1 and Figure 4.2.  Statistically significant differences 
in median pore radius (n = 3, p < 0.006), percent effective porosity (n = 
3, p < 0.002) and tortuosity (n = 3, p < 0.0004) were observed between 
the direct compression and hot-melt extruded tablets as shown in Table 1.  
The median pore radius was smaller and the tablets less porous when 
prepared by hot-melt extrusion (137 – 392 Å, 0.4 – 2.3% porosity and 
41.8 – 321 tortuosity) than by direct compression (475 – 1439 Å, 3.1 – 
6.5% porosity and 1.3 – 6.9 tortuosity).  Adsorption and binding studies 
did not reveal any interactions.  Complete drug recovery was obtained in 
samples dissolved in ethanol.  Thus, the differences in release rate are 
due to the bonding mechanism of the particles in the two tableting 
techniques.  Ethyl cellulose has been reported to be ductile and the 
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predominant mechanism during compaction is plastic deformation [146].  
During hot-melt extrusion, solid bridges are formed upon cooling.   
The extrusion temperatures were above the melting point of 
guaifenesin but below the glass transition temperature of ethyl cellulose.  
The molten drug can act as a solvent for the polymeric particles.  
Polymeric particles that do not go into solution are softened at elevated 
temperatures and deformed by the rotating screw during extrusion.  Upon 
cooling, extensive solid bridges are formed between the particles resulting 
in a smaller pore radius and more tortuous network.  These results 
demonstrate that densification of the molten mass during extrusion occurs 
to a greater extent relative to compaction of the powder during 
compression. 
Thermal treatment of amorphous polymers has also been shown to 
decrease polymer free volume [2].  Elevated temperatures and high 
pressures during hot-melt extrusion followed by cooling significantly 
impact the free volume.  Polymer chain motion and free volume increase 
with temperature allowing molten guaifenesin molecules to enter these 
voids.  Upon cooling, the guaifenesin molecules remain dispersed in these 
domains.  The net effect is an increase in the degree of packing and a 
reduction in free volume.  Diffusion of molecules through amorphous 
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polymers is governed by free volume and packing.  Thus, a decrease in 
drug transport is anticipated when the free volume decreases and packing 
order increases.  
The miscibility of guaifenesin in ethyl cellulose was studied by 
modulated differential scanning calorimetry.  The glass transition 
temperature of ethyl cellulose was found to be 129.3°C (Figure 4.4, A) 
and the melting point of guaifenesin was found to be 85.6°C (Figure 4.4, 
B).  The melting point of guaifenesin can be observed in the thermograms 
of the physical mixtures (Figure 4.4, C & F).  Thermograms of the hot-
melt extrudates processed at 80 - 90°C show a weak melt transition about 
9°C below the melting point of guaifenesin (Figure 4.4, D & G).  Strong 
thermal transitions corresponding to the melting point of guaifenesin are 
not observed in the extrudates processed at 90 – 100°C (Figure 4.4, E & 
H).  These results suggest that guaifenesin was miscible with ethyl 
cellulose while in the molten state and did not recrystallize after cooling.  
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Figure 4.4:  Modulated differential scanning calorimetry profiles of ethyl 
cellulose, guaifenesin, physical mixtures and hot-melt extrudates. 
 
A. Ethyl cellulose 
B. Guaifenesin 
C. Physical mixture of 30% guaifenesin and 70% “Coarse” ethyl cellulose 
D. Hot-melt extrudate of 30% guaifenesin and 70% “Coarse” ethyl 
cellulose processed at 80, 85, 85, 90°C 
E. Hot-melt extrudate of 30% guaifenesin and 70% “Coarse” ethyl 
cellulose processed at 90, 105, 105, 110°C 
F. Physical mixture of 30% guaifenesin and 70% “Fine” ethyl cellulose 
G. Hot-melt extrudate of 30% guaifenesin and 70% “Fine” ethyl cellulose 
processed at 80, 85, 85, 90°C 
H. Hot-melt extrudate of 30% guaifenesin and 70% “Fine” ethyl cellulose 
processed at 90, 105, 105, 110°C 
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4.5.3  The Influence of Compaction Force on Drug Release 
The release rate of guaifenesin decreased with increasing 
compaction force in tablets prepared by direct compression (Figures 4.1 & 
4.2).  At higher compaction forces, the powder bed densifies to a greater 
extent and eliminates more of the air in the powder bed and voids in 
individual particles.  The increased densification process results in a tablet 
with greater mechanical strength, lower porosity and higher tortuosity.  
These results were confirmed by the helium pycnometry and mercury 
porosimetry measurements (Table 4.1).  The median pore radius and 
percent effective porosity decreased and tortuosity increased as the 
compaction force was raised.   
4.5.4  The Influence of Hot-Melt Extrusion Temperature on Drug 
Release 
The guaifenesin release rate in hot-melt extruded tablets decreased 
as the extrusion temperature increased.  Guaifenesin release rates from 
matrix tablets extruded at 80 – 90°C were statistically different from those 
prepared at 90 – 110°C, according to the model independent approach (f1 
= 29.3 and f2 = 30.6).  Statistically significant differences in median pore 
radius (n = 3, p < 0.01), percent effective porosity (n = 3, p < 0.0002) 
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and tortuosity (n = 3, p < 0.002) were observed between tablets 
prepared at the two extrusion temperatures.  The median pore radius was 
larger, the tablets more porous and tortuous when extruded at 80 – 90°C 
(264 – 392 Å, 1.0 – 2.3% porosity and 41.8 – 53.2 tortuous) than when 
extruded at 90 – 110°C (137 – 351 Å, 0.4 – 0.7% porosity and 125 – 321 
tortuous).   
Modulated differential scanning calorimetry revealed small melting 
transitions in the extrudates processed at low temperatures (Figure 4.4, D 
& G).  These thermal events were absent in the extrudates processed at 
higher temperatures suggesting that a molecular dispersion was formed to 
a greater extent at higher extrusion temperatures.  Since both processing 
temperatures were above the melting point of guaifenesin but below the 
glass transition temperature of ethyl cellulose, it is likely guaifenesin 
dissolved the ethyl cellulose particles more readily at higher temperatures.  
The resulting solid dispersion was less porous and more tortuous than 
that formed at lower processing temperatures. 
The stability of polymers used in hot-melt extrusion has been 
previously investigated [3, 6, 7, 13].  The stability of ethyl cellulose during 
hot-melt extrusion by measuring molecular weight using gel permeation 
 134
chromatography has been described [2, 32, 153, 154].  These researchers 
report that ethyl cellulose molecular weight was stable during extrusion 
within the processing conditions employed in this study.  Degradation of 
ethyl cellulose was observed at high temperatures.  The onset of 
degradation of ethyl cellulose was found to occur at ~190°C and 
discoloration at temperatures above 205°C. 
Scanning electron microscopy was used to investigate the surface 
morphology of the hot-melt extruded matrix tablets prior to dissolution 
testing and the data are presented in Figures 4.5 – 4.9.  The surface 
morphology of the hot-melt extruded tablets was found to depend upon 
extrusion temperature.  At low extrusion temperatures, individual particles 
are visible (Figures 4.5 and 4.7).  These particles are likely responsible for 
the weak melting transitions observed in the DSC experiments (Figure 4.4, 
D & G).  Few particles and pores are visible and the tablet surface was 
found to have a striated appearance (Figure 4.6 and 4.8) when processed 
at higher processing temperatures.  The striated appearance is the result 
of “rifling” or shearing of the molten mass on the die wall upon exit from 
the extruder (Figure 4.9).  
 135
 
 
 
 
 
 
Figure 4.5:  SEM micrographs of the surface of hot-melt extruded matrix 
tablets containing 30% guaifenesin and 70% “Fine” ethyl cellulose processed at 
80, 85, 85, 90°C viewed at 1,000 X magnification. 
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Figure 4.6:  SEM micrographs of the surface of hot-melt extruded matrix 
tablets containing 30% guaifenesin and 70% “Fine” ethyl cellulose 
processed at 90, 105, 105, 110°C viewed at 1,000 X magnification. 
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Figure 4.7:  SEM micrographs of the surface of hot-melt extruded matrix 
tablets containing 30% guaifenesin and 70% “Coarse” ethyl cellulose 
processed at 80, 85, 85, 90°C viewed at 1,000 X magnification. 
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Figure 4.8:  SEM micrographs of the surface of hot-melt extruded matrix 
tablets containing 30% guaifenesin and 70% “Coarse” ethyl cellulose 
processed at 90, 105, 105, 110°C viewed at 1,000 X magnification. 
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Figure 4.9:  SEM micrographs of the surface of hot-melt extruded matrix 
tablets containing 30% guaifenesin and 70% “Coarse” ethyl cellulose 
processed at 90, 105, 105, 110°C viewed at 10,000 X magnification. 
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4.5.5  Pore Characteristics Prior to & After Dissolution Testing 
The pore characteristics of the hot-melt extruded matrix tablets 
measured after dissolution testing are reported in Table 4.1.  Tablets 
prepared by direct compression could not be analyzed due to matrix 
erosion and disintegration during dissolution testing.  Statistically 
significant differences were observed in median pore radius (n = 3, p 
<0.01), percent effective porosity (n = 3, p <0.0006) and tortuosity (n = 
3, p <0.00004).  Following dissolution testing, the median pore radius 
increased from 137 – 392 Å to 521 – 642 Å, the porosity increased from 
0.4 – 2.3% to 7.8 – 8.7%, and the tortuosity decreased from 53.2 – 321 
to 4.4 – 5.2.  Prior to dissolution testing, the pores are primarily voids 
within the matrix.  Following dissolution, the increase in median pore size 
and porosity is due to capillary diffusion of guaifenesin from the matrix.  
As guaifenesin particles on the outer surface of the tablet diffuse, a less 
tortuous pore network is created. 
The surface morphology of the hot-melt extruded matrix tablets 
following a 24 hour dissolution test is presented in Figure 4.10 and 4.11.  
When viewed at 1,000 x magnification, the tablet surface was found to be 
smooth and no pores were visible.  However, when viewed at 10,000 x 
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magnification, pores were clearly evident.  The tablet surface after 
dissolution testing was smoother due to hydrodynamic shearing forces 
from the agitated dissolution medium and the greater number of pores is 
due to capillary diffusion of guaifenesin.   
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Figure 4.10:  SEM micrographs at 1,000X magnification of the surface of 
hot-melt extruded matrix tablets containing 30% guaifenesin and 70% 
“Coarse” ethyl cellulose processed at 90, 105, 105, 110°C measured after 
24 hour dissolution testing. 
 
 
 
 143
 
 
 
 
 
 
 
 
Figure 4.11:  SEM micrographs at 10,000X magnification of the surface 
of hot-melt extruded matrix tablets containing 30% guaifenesin and 70% 
“Coarse” ethyl cellulose processed at 90, 105, 105, 110°C measured after 
24 hour dissolution testing. 
 144
4.5.6  Determination of Drug Release Kinetics 
The dissolution data were plotted according to the Higuchi equation 
(Figures 4.12 and 4.13) and the kinetic data are shown in Table 4.2.  A 
higher deviation from the theoretical prediction was observed for matrix 
tablets prepared by direct compression using “coarse” ethyl cellulose at 
low compaction forces.  The mechanism of release from these tablets was 
due to both diffusion and erosion.  These tablets possessed very large 
pores and were considerably more porous and less tortuous than tablets 
prepared with “fine” ethyl cellulose.  The tablets prepared by direct 
compression were completely eroded at the conclusion of the dissolution 
test, irrespective of the particle size of ethyl cellulose. 
In contrast to directly compressed tablets, tablets prepared by hot-
melt extrusion exhibited much slower drug release and a lag time was 
present.  The hot-melt extruded tablets prepared by with “fine” ethyl 
cellulose demonstrated an initial lag time in drug release compared to 
those prepared with “coarse” ethyl cellulose.  The lag time is indicated by 
the positive time intercept on the regression lines predicted by the Higuchi 
model.  Lag times correspond to the time necessary for the dissolution 
medium to wet the tablet matrix and enter the pores.  These tablets have 
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a lag time because they have a smaller pore size, are less porous and 
more tortuous.   
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Figure 4.12:  Higuchi Diffusion model fitting of the guaifenesin release 
data from matrix tablets prepared by direct compression and hot-melt 
extrusion. 
 
Matrix tablets prepared using “Fine” ethyl cellulose (325 – 80 Mesh) 
 
o Direct Compression, 10 kN 
à Direct Compression, 30 kN 
D Direct Compression, 50 kN 
· Hot-Melt Extrusion, 80, 85, 85, 90°C 
¨ Hot-Melt Extrusion, 90, 105, 105, 110°C 
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Figure 4.13:  Higuchi Diffusion model fitting of the guaifenesin release 
data from matrix tablets prepared by direct compression and hot-melt 
extrusion. 
 
Matrix tablets prepared using “Coarse” ethyl cellulose (80 – 30 Mesh) 
 
o Direct Compression, 10 kN 
à Direct Compression, 30 kN 
D Direct Compression, 50 kN 
· Hot-Melt Extrusion, 80, 85, 85, 90°C 
¨ Hot-Melt Extrusion, 90, 105, 105, 110°C 
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Table 4.2:  Kinetic data from regression fitting to Higuchi Diffusion Model giving the rate constant k 
(g/cm2s1/2), the y-intercept (g/cm2), the correlation coefficient r2, the apparent diffusion coefficient Dapp 
(cm2/s) and the diffusion coefficient Ds from the plot of drug release (g/cm2) against the square root of 
time (s1/2). 
Processing Conditions k  (g/cm2s1/2´103) 
y-int.  
(g/cm2´103) r
2 Dapp (cm2/s ´106) 
Ds 
(cm2/s ´103) 
“Fine” Ethyl Cellulose (325 - 80 mesh) 
DC 10 kN 1.18 0.04 0.995 86.6 9.9 
DC 30 kN 1.10 - 4.03 0.975 75.2 11.9 
DC 50 kN 1.01 - 6.02 0.981 63.1 14.1 
HME 80, 85, 85, 90°C 0.43 0.85 0.999 11.3 60.2 
HME 90, 105, 105, 110°C 0.37 - 0.25 0.997 8.35 669.7 
“Coarse” Ethyl Cellulose (80 - 30 mesh) 
DC 10 kN 3.08 - 4.68 0.899 598 12.0 
DC 30 kN 2.48 - 6.32 0.961 386 14.2 
DC 50 kN 2.19 - 10.4 0.971 300 16.2 
HME 80, 85, 85, 90°C 0.38 7.21 0.980 8.90 16.2 
HME 90, 105, 105, 110°C 0.36 1.69 0.998 7.91 141.3 
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4.6  CONCLUSIONS 
The results of this study demonstrate that the guaifenesin release 
rate was dependent upon the particle size of ethyl cellulose and the 
processing conditions employed to prepare the tablets.  The guaifenesin 
release rate was slower in tablets prepared with the “fine” ethyl cellulose 
particle size fraction due to the presence of fewer soluble drug clusters 
within the matrix.  Tablets prepared by hot-melt extrusion exhibited 
considerably slower drug release relative to those prepared by direct 
compression.  Thermal analysis demonstrated that guaifenesin was 
dispersed in ethyl cellulose at the molecular level in tablets prepared by 
hot-melt extrusion.  The surface morphology of the hot-melt extruded 
tablets was found to depend upon processing temperature.  The 
guaifenesin release rate also decreased with increasing compaction force 
in tablets prepared by direct compression due to greater densification of 
the powder bed.  Analysis of the tablet pore characteristics could be 
correlated to the observed dissolution results.  Drug release in hot-melt 
extruded tablets was found to be in good agreement with the Higuchi 
Diffusion model.  Tablets prepared by direct compression using “coarse” 
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ethyl cellulose were found to release guaifenesin by both diffusion and 
erosion.  
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CHAPTER 5  THE INFLUENCE OF GUAIFENESIN AND 
KETOPROFEN ON THE PROPERTIES OF HOT-MELT 
EXTRUDED POLYETHYLENE OXIDE FILMS 
5.1 ABSTRACT 
Films containing polyethylene oxide (PEO) and a model drug, either 
guaifenesin (GFN) or ketoprofen (KTP), were prepared by hot-melt 
extrusion.  The thermal properties of the hot-melt extruded films were 
investigated using differential scanning calorimetry (DSC).  Scanning 
electron microscopy (SEM) was used to examine the surface morphology 
of the films, and wide angle x-ray diffraction (XRD) was used to 
investigate the crystalline properties of the polymer, drugs and physical 
mixtures as well as the solid state structure of the films.  The stability of 
the polymer was studied using gel permeation chromatography.  The 
mechanical properties, including percent elongation and tensile strength 
of the films were determined on an Instron according to ASTM 
procedures.  The Hoftyzer / van Krevelen method for calculation of the 
Hansen solubility parameter was calculated to estimate the likelihood of 
drug-polymer miscibility.  Both GFN and KTP were stable during the 
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extrusion process.  XRD suggested that GFN crystallized from the melt 
upon cooling, but KTP formed a solid solution.  Melting points 
corresponding to the crystalline drugs were not observed in the films by 
DSC analysis.  Crystallization of GFN on the surface of the film could be 
observed using SEM at all concentrations studied, but KTP crystallization 
did not occur until reaching the 15% level.  GFN and KTP were found to 
decrease drive load, increase PEO stability and plasticize PEO the polymer 
during extrusion.  The Hansen solubility parameters calculated using the 
Hoftyzer / van Krevelen method predicted miscibility between PEO and 
KTP and poor miscibility between PEO and GFN.  The predictions of the 
solubility parameters were in agreement with the XRD and SEM results.  
The percent elongation decreased with increasing GFN concentrations, but 
significantly increased with increasing KTP concentrations.  Both GFN and 
KTP decreased the tensile strength of the extruded film. 
 
5.2  INTRODUCTION 
The transdermal and transmucosal route of drug administration 
offers many advantages to other methods of drug delivery, especially 
when the drug undergoes either a substantial first pass effect or local 
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therapy is desired.  Polymeric films are used to deliver drugs in 
transdermal and transmucosal systems and may function as backing 
materials, drug reservoirs, micro-porous or semi-permeable membranes 
and bioadhesive layers.  Transdermal and transmucosal films for drug 
delivery are generally produced by casting from organic or aqueous 
solvent systems.  In addition to long processing times, high cost and 
environmental concerns, several researchers have reported that cast films 
are not mechanically stable [10, 87, 89, 155-157].  The instability of cast 
films has been attributed to polymer chain relaxation, moisture absorption 
and polymer-plasticizer interaction during storage.   
Hot-melt extrusion has received considerable attention in the 
pharmaceutical industry.  Several research groups have demonstrated the 
hot-melt extrusion technique to be a viable method to prepare 
pharmaceutical dosage forms including granules [2], pellets [4, 158], 
sustained release tablets [5-7] and topical and transdermal drug delivery 
systems [10-17].  A number of studies have recently shown the potential 
of hot-melt extrusion techniques to form solid solutions and solid 
dispersions [5, 30, 76, 91, 159].   
The formation of a solid dispersion has been found to influence the 
properties of the dosage form.  Aitken-Nichol and coworkers found that 
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hot-melt extrusion was a viable method to produce thin, flexible films for 
topical drug delivery using Eudragit E100 [10].  Hot-melt extruded films 
were compared to cast films and differences were observed in the 
dissolution rate and mechanical properties.  These researchers reported 
that lidocaine hydrochloride was able to plasticize the hot-melt extruded 
film.  The authors concluded that the differences in dissolution rate and 
mechanical properties were due to dissolution of the drug in polymer 
when prepared by hot-melt extrusion.     
Polyethylene oxide has been widely used in a variety of dosage 
forms [5, 93, 94, 96, 97], including transdermal and transmucosal dosage 
forms [11, 95, 160-163].  PEO is semi-crystalline, bioadhesive and 
mucoadhesive due to its water solubility, hydrophilicity, high viscosity, 
ability to form hydrogen bonds and biocompatibility [164].  PEO has been 
previously studied for the production of hot-melt extruded tablets [5, 7] 
and as an adjuvant in hot-melt extruded hydroxypropylcellulose films [13].   
Despite its wide usage, few studies have been reported in the 
scientific literature on the properties of PEO films as a drug reservoir and 
bioadhesive layer for transdermal drug delivery.  Furthermore, there are 
no reports in the literature on the influence of drugs on the properties of 
hot-melt extruded polyethylene oxide films.  Therefore, the objectives of 
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this study were to investigate the physicochemical and mechanical 
properties of hot-melt extruded PEO films containing either guaifenesin or 
ketoprofen as model drugs.  Guaifenesin and ketoprofen were used as 
model drugs used in this study.  Both compounds are crystalline with poor 
water solubility. 
 
5.3  MATERIALS AND METHODS 
5.3.1  Materials 
Guaifenesin and ketoprofen were purchased from Spectrum 
Laboratory Products (Gardena, CA).  Polyethylene Oxide (Polyox WSR-
N80, molecular weight 200,000) was kindly donated by the Dow Chemical 
Company (Midland, MI).  HPLC solvents were purchased from EM Science 
(Gibbstown, NJ). 
5.3.2  Methods 
5.3.2.1  Hot-Melt Extrusion 
Model formulations containing the polymer and 0, 5, 10, 15 and 
30% (w/w) of either drug were prepared by geometric dilution, then 
introduced into a V Blender (Blend MasterÒ,Patterson-Kelley, East 
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Stroudsburg, PA) and mixed for 15 minutes.  The powder blend (250 
grams) was fed into a single-screw Randcastle Extruder (Model RC 0750, 
Cedar Grove, NJ) equipped with a Nitralloy 135M screw (3:1 compression 
ratio with flight configuration containing feed, compression and mixing 
sections) and a 6 inch flex film die.  The screw speed was 40 rpm.  The 
three heating zones and die temperature were set to 60, 75, 90 and 
100°C and allowed to equilibrate.  The residence time of the materials in 
the extruder was approximately 2 – 3 minutes.  The films were wound 
and collected in rolls.  The film thickness ranged from 0.30 to 0.45 mm 
and the width was 10 cm. 
5.3.2.2  Drug Content 
The film samples were analyzed for guaifenesin content using a 
Waters (Milford, MA) high performance liquid chromatography (HPLC) 
system with a photodiode array detector (Model 996) extracting at 276 
nm.  The mobile phase was a mixture of water:methanol:glacial acetic 
acid in volume ratios of 600:400:15.  The solvents were vacuum filtered 
through a 0.45 mm nylon membrane and degassed by sonication.  
Samples were dissolved in mobile phase and pre-filtered through a 0.45 
mm membrane (Gelman Laboratory, GHP Acrodisc).  An auto sampler 
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(Model 717plus) was used to inject 20mL samples.  The data were 
collected and integrated using EmpowerÒ Version 5.0 software.  The 
column was an Alltech AlltimaÔ C18 3 mm, 150 ´ 4.6 mm.  The flow rate 
was 1.0 ml/min.  The retention time of the guaifenesin was 4 minutes.  
Linearity was demonstrated from 2 to 200 mg/ml (R2 = 0.997) and 
injection repeatability was 0.35% relative standard deviation for 10 
injections. 
 Samples were analyzed for ketoprofen using HPLC extracting at 
256 nm.  The column was an Alltech AlltimaÔ C18 3 mm, 150 ´ 4.6 mm 
and the mobile phase was 55% acetonitrile, 45% 20mM pH 4 acetate 
buffer.  The flow rate was 1 ml/min and the ketoprofen retention time 
was 5.2 minutes.  Linearity was demonstrated from 1 to 200 mg/ml (R2 = 
0.995) and injection repeatability was 0.62% relative standard deviation 
for 10 injections. 
5.3.2.3  Wide Angle X-Ray Diffraction 
The crystalline properties of the film samples were examined by 
wide angle X-ray diffraction.  Film samples measuring  20 ´ 15 mm were 
introduced to a Philips 1710 X-ray diffractometer with a CuKa target, 
diffracted beam monochromatic filter and variable divergent slit (Philips 
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Electronic Instruments, Inc., Mahwah, NJ) using Jade 5 XRD pattern 
processing software (Materials Data, Inc., Irvine, CA).  The voltage was 
set to 40 kV and the current was set to 40 mA.  Samples were analyzed in 
the 2-Theta range from 5-55° using a 0.05° step size with a 1-second 
dwell time at each step.   
5.3.2.4  Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) was used to characterize 
the thermal properties of the polymer, drug, physical mixtures and hot-
melt extruded films.  The DSC instrument was a model 2920 from TA 
Instruments (New Castle, DE) running in standard mode and equipped 
with Universal Analysis 2000 software.  Ultrahigh purity nitrogen was used 
as the purge gas at a flow rate of 150 ml/min.  The sample was weighed 
to 10 ± 5 mg and placed in aluminum pans (Kit 0219-0041, Perkin-Elmer 
Instruments, Norwalk, CT) and crimped with an aluminum lid.  The 
temperature ramp speed was 10°C per minute from 25°C to 115°C for all 
studies. 
5.3.2.5  Scanning Electron Microscopy 
Scanning electron microscopy was used to study the surface 
morphology of the hot-melt extruded films.  The samples were mounted 
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on an aluminum stage using adhesive carbon tape and placed in a low 
humidity chamber for 12 hours prior to analysis.  Samples were coated 
with gold-palladium for 60 seconds under an argon atmosphere using a 
Pelco® Model 3 Sputter Coater (Ted Pella, Inc., Redding, CA) in a high 
vacuum evaporator equipped with an omni-rotary stage tray.  Scanning 
electron microscopy was performed using a Hitachi S-4500 field emission 
microscope operating at an accelerating voltage of 10 kV and a 15 mA 
emission current.  Images were captured with QuartzÒ PCI software 
(Quartz Imaging Corporation, Vancouver, B.C. Canada). 
5.3.2.6  Gel Permeation Chromatography 
The weight average molecular weight of PEO was determined as 
previously reported [7].  Briefly, the mobile phase was double-distilled 
water containing 0.1 M sodium nitrate.  All standards and samples were 
prepared at 0.5% w/w concentrations in mobile phase under gentle 
agitation on a radial shaker (Aberbach Corp, Ann Arbor, MI) for 12 hours 
and injected immediately.  A Waters analytical system used for analysis 
included a WISP model 710B auto sampler (100ml sample injection 
volume), model 510 pump, UltrahydrogelÒ Columns (2000 and 1000 in 
series) and a model 410 differential refractometer as the detector.  The 
 160
data were collected using EmpowerÒ Version 5.0 software.  A third order 
calibration curve (R2 = 0.99) was constructed using PEO standards 
(Polymer Standards Service, Silver Spring, MD) with peak molecular 
weights ranging from 4,450 to 1,700,000.  The flow rate was 0.8 ml/min 
and the columns were held at an operating temperature of 35°C during 
analysis.  Injection precision was found to have a relative standard 
deviation of 1.3% for 10 injections. 
5.3.2.7  Mechanical Testing 
The stress and strain mechanical properties of the films were 
determined utilizing an Instron 4201 testing apparatus operating in 
accordance with the standard test method for tensile properties of thin 
plastic sheeting by the American Society for Testing Materials, method 
D882-02 [165].  The film samples were stored for 12 hours prior to testing 
to equilibrate at 25°C and 60% relative humidity.  Six samples from each 
film formulation were cut in the direction of machine flow into rectangles 
(150 mm long by 10 mm wide).  Twenty five millimeters of tape was 
applied to each end to prevent grip rupture.  The Instron was set with a 
full scale load of 50 N and a cross head speed of 25 mm/min.  The initial 
grip separation was 100 mm.  The thickness of each rectangle was 
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measured along the centerline in 10 places and recorded.  Testing 
conditions for all films were 25°C and 60% relative humidity.  The 
samples were extended until they ruptured and the load, stress, strain 
and peak load were calculated.   
5.3.2.7  Statistical Analysis 
One-way analysis of variance (ANOVA) was used to determine 
statistically significant differences between results.  Results with p-values 
< 0.05 were considered statistically significant. 
 
5.4  RESULTS & DISCUSSION 
5.4.1  Physicochemical Characterization of Hot-melt Extruded 
PEO Films and Films containing Guaifenesin and 
Ketoprofen 
The hot-melt extruded PEO film and the hot-melt extruded films 
containing guaifenesin and ketoprofen were clear, homogenous and 
flexible.  Both GFN and KTP were found to be stable during hot-melt 
extrusion.  The drug content was assayed using HPLC.  Excellent 
agreement was found between the formulated content and the values 
 162
determined after thermal processing (³99%).  There was no change in the 
peak retention time and no additional peaks were observed.   
PEO is a semi-crystalline polymer, and GFN and KTP are crystalline 
drugs.  The X-ray diffraction (XRD) patterns of PEO, GFN, KTP, physical 
mixtures and the hot-melt extruded films are presented in Figures 5.1 and 
5.2.  The highest crystalline PEO peak occurred at a 2q angle of 23.5 and 
a smaller, distinct peak was also observed at 19.1 2q angles.  GFN has 
distinct crystalline peaks at 12.1, 13.6 and 20.8 2q angles and a series of 
smaller peaks at 22.55, 23.80, 25.50, 27.5 2q angles.   
The PEO crystalline peaks at 19.1 and 23.5° 2q° were observed in 
the drug free hot-melt extruded film, but were broad and less intense 
than the powder sample.  The reduction in peak intensity was associated 
with a decrease in crystallinity and the peaks became more broad due to a 
wider distribution of crystal sizes.  The diffraction patterns of the physical 
mixtures composed of PEO and GFN exhibit crystalline peaks 
corresponding to PEO (19.1, 23.5 2q°), but the XRD technique was not 
able to detect GFN peaks until the GFN concentration reached the 10% 
level.  PEO and GFN crystalline peaks were also present in the hot-melt 
extruded films at the higher GFN levels.  At GFN loads of 10, 15 and 30%, 
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the GFN peaks at 12.1°, 13.6° and 20.8° were more intense in the hot-
melt extruded films than in the physical mixtures.  The increase in peak 
intensity following thermal treatment suggests that two distinct phases 
formed upon cooling.  The XRD technique is sensitive to crystal 
orientation.  After hot-melt extrusion, the increase in peak intensity is 
likely due to a preferential orientation of crystals within the film. 
The largest crystalline peak in KTP can be observed at a 2q angle 
of 22.85 with smaller peaks at 6.4, 14.4 and 18.4 2q angles (Figure 5.2).  
The diffraction patterns of the physical mixtures composed of PEO and 
KTP also exhibit PEO crystalline peaks (19.1, 23.5 2q angles).  However, 
XRD was not able to detect KTP peaks until the KTP concentration in the 
film reached 10%.  In contrast to the GFN film, the diffraction pattern of 
the hot-melt extruded KTP film showed peaks corresponding to PEO, but 
peaks associated with KTP were absent.  This finding suggests that KTP 
was fully dissolved in the polymer following extrusion. 
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Figure 5.1: Wide angle X-Ray diffraction profiles of PEO powder, 
guaifenesin, hot-melt extruded PEO film, physical mixtures of PEO and 
guaifenesin and hot-melt extruded films of PEO and guaifenesin. 
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Figure 5.2:  Wide angle X-Ray diffraction profiles of PEO powder, 
ketoprofen, hot-melt extruded PEO film, physical mixtures of PEO and 
ketoprofen and hot-melt extruded films of PEO and ketoprofen. 
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The thermal properties of the polymer, drugs, physical mixtures 
and films were investigated using DSC.  GFN in its crystalline form 
produced an endotherm representing its melting point at 85.6°C (Figure 
5.3).  The PEO melting point can be observed at 68.9°C.  The physical 
mixture of PEO and GFN exhibits a broad peak at 67.6°C.  This thermal 
transition was more broad than the individual pure materials and suggests 
that melting of PEO and solubilization of GFN occurred simultaneously.  A 
thermal transition associated with a GFN melting point is not evident in 
the physical mixture or the drug loaded films.  Indeed, these findings 
contradict the presence of GFN crystallinity determined by XRD.  It can be 
reasoned that GFN and PEO were miscible in the molten state at elevated 
temperatures, but GFN crystallized into a separate phase upon cooling.  
The GFN recrystallization process could not be captured on the DSC time 
scale.  The presence of GFN crystals in the films is reinforced by the 
significant depression of the PEO melting point.  Pure materials generally 
exhibit sharp melting points.  The introduction of an impurity into a 
crystalline material causes a broadening of the melting range and often, a 
depression in the melting point.  As the GFN concentration in the film 
increased, the thermogram exhibited a depression and broadening of the 
 167
PEO melting point.  The reduction and broadening of the melting 
transition also suggests the presence of smaller crystals and a wider 
distribution of crystal sizes. 
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Figure 5.3:  Differential Scanning Calorimetry profiles of PEO, 
guaifenesin, a physical mixture of GFN and PEO, and GFN loaded films. 
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Ketoprofen loaded films were also studied by DSC (Figure 5.4).  
KTP in its crystalline form produced an endotherm at 96.2°C 
corresponding to the melting point.  Physical mixtures and hot-melt 
extruded films of PEO and KTP show a broad peak at 65°C corresponding 
to PEO, but do not exhibit an endotherm corresponding to KTP.  Similar to 
the GFN films, as the KTP concentration in the film increased, the 
endotherm representing the PEO melting point was depressed to a greater 
extent and became broader.  These results support the conclusions from 
the XRD data that KTP dissolved in the molten PEO during extrusion and 
did not recrystallize upon cooling. 
Scanning electron microscopy was used to examine the surface 
morphology of films (Figures 5.5 – 5.12).  The drug free PEO film has a 
clear and homogenous surface with few visible crystals (Figure 5.5).  
However, the micrograph of the GFN loaded films revealed that crystal 
formation had occurred.  Surface crystallization increased with increasing 
GFN concentrations (Figure 5.6 – 5.9).  Furthermore, crystal orientation 
on the surface can be observed.  In contrast, crystallization on the surface 
of the KTP loaded films was not observed until reaching the 15% level 
(Figure 5.10 – 5.12). 
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Figure 5.4:  Differential Scanning Calorimetry profiles of PEO, 
ketoprofen, a physical mixture of KTP and PEO, and KTP loaded films. 
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Figure 5.5:  SEM micrograph of the surface morphology of hot-melt 
extruded PEO film at 100 x magnification. 
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Figure 5.6:  SEM micrograph of the surface morphology of hot-melt 
extruded film containing 95% PEO and 5% GFN at 100 x magnification. 
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Figure 5.7:  SEM micrograph of the surface morphology of hot-melt 
extruded film containing 90% PEO and 10% GFN at 100 x magnification. 
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Figure 5.8:  SEM micrograph of the surface morphology of hot-melt 
extruded film containing 85% PEO and 15% GFN at 100 x magnification. 
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Figure 5.9:  SEM micrograph of the surface morphology of hot-melt 
extruded film containing 70% PEO and 30% GFN at 100 x magnification. 
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Figure 5.10:  SEM micrograph of the surface morphology of hot-melt 
extruded film containing 95% PEO and 5% KTP at 100 x magnification. 
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Figure 5.11:  SEM micrograph of the surface morphology of hot-melt 
extruded film containing 90% PEO and 10% KTP at 100 x magnification. 
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Figure 5.12:  SEM micrograph of the surface morphology of hot-melt 
extruded film containing 85% PEO and 15% KTP at 100 x magnification. 
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Polymers are subject to mechanical, thermal and oxidative 
degradation during hot-melt extrusion.  We have previously reported the 
stability of high molecular weight PEO in matrix tablets prepared by hot-
melt extrusion [7].  Similarly, gel permeation chromatography was used in 
the present study to determine the molecular weight of PEO before and 
after hot-melt extrusion (Table 5.1).  The weight average molecular 
weight of PEO decreased 6.8% after thermal processing when processed 
without GFN or KTP.  GFN and KTP were found to reduce PEO molecular 
weight loss and to decrease the load on the extruder motor.  A decrease 
in drive load suggests a reduction in melt viscosity (shear thinning), 
degradation (formation of lower molecular weight polymer chains) and or 
an improvement in polymer chain mobility.  As the GFN and KTP 
concentration increased in the film, the drive amperage decreased and the 
stability of PEO increased.  At higher drug concentrations, no change in 
molecular weight of the polymer was observed following the hot-melt 
extrusion process.  These results suggest that GFN and KTP plasticize PEO 
during extrusion. 
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Table 5.1:  Stability of PEO in Hot- Melt Extruded Films containing either 
Guaifenesin or Ketoprofen as Determined by Gel Permeation 
Chromatography. 
 
Formulation 
PEO GFN KTP 
After Extrusion 
Mw ´ 103 
% Change Drive Current (A) 
100   176 ± 14 - 6.8 2.2 – 2.4 
95 5  180 ± 12 - 4.8 1.9 – 2.3 
90 10  183 ± 11 - 3.2 1.6 – 1.8 
85 15  190 ± 12 + 0.5 1.4 – 1.6 
70 30  191 ± 14 + 1.1 1.4 – 1.6 
95  5 184 ± 8 - 2.6 1.5 – 1.8 
90  10 186 ± 11 - 1.6 1.1 – 1.6 
85  15 188 ± 13 - 0.5 0.7 – 1.0 
 
Unextruded PEO Mw 189 ± 9 
Zone Temperatures: 50, 60, 70 and 80°C 
Screw Speed:  40 rpm 
Molecular weights are reported as mean ± standard deviation, n = 6. 
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5.4.2  Calculated Solubility Parameters of Guaifenesin, 
Ketoprofen and Polyethylene Oxide and their Relationship 
to the Experimental Results. 
 
Solubility parameters (d) have been used successfully to predict the 
miscibility of drugs with excipients and polymers in solid dispersions [38, 
166-168].  Greenhalgh et al. suggested that interactions between polar 
(dp) and hydrogen bonding groups (dh) significantly affect solubility and 
should be incorporated into the estimation of Hildebrand solubility 
parameters, which account for dispersive forces (dd) only.  The method of 
Hoftyzer and van Krevelen [169] can be used to estimate the Hansen 
solubility parameter with the incorporated values (dt) as described below:   
222
hpdt dddd ++=    (Equation 5.1) 
Compounds with similar values for d are likely to be miscible 
because the energy of mixing from intramolecular interactions is balanced 
with the energy of mixing from intermolecular interactions.  The difference 
between the solubility parameters (Dd) of two materials gives an 
estimation of the likelihood that they will be miscible.  Greenhalgh et. al. 
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demonstrated that compounds with Ddt < 7 Mpa1/2 were likely to be 
miscible and compounds with Ddt > 10 Mpa1/2 were likely to be immiscible.   
 Table 5.2 shows the interaction parameters and calculated 
solubility parameters for guaifenesin, ketoprofen and polyethylene oxide.  
The difference between the calculated solubility parameters of the 
polymer and the drugs predict that PEO and KTP are likely to be miscible, 
but that PEO and GFN are likely to be immiscible.  Thus, the Hansen 
solubility parameter calculated using the method of Hoftyzer and van 
Krevelen supports the results of the XRD and SEM studies. 
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Table 5.2:  Calculated Interaction Parameters and Solubility Parameters 
for Guaifenesin, Ketoprofen and Polyethylene Oxide. 
 
 dd dp dh dt (Mpa1/2) 
Guaifenesin 20.3 .31 18.4 27.5 
Ketoprofen 18.7 .18 7.5 20.2 
Polyethylene Oxide 17.8 .56 9.1 20.0 
Ddt (GFN – PEO) = 7.5 Ddt (KTP – PEO) = 0.2 
 
dd is the dispersion forces parameter, dp is the polar interaction 
parameter, dh is the hydrogen bonding parameter and dt is the total 
solubility parameter calculated according to equation 5.1. 
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5.4.3  The Influence of Guaifenesin and Ketoprofen on the 
Mechanical Properties of Hot-melt Extruded Polyethylene 
Oxide Films 
The tensile strength and percent elongation of the drug free and 
drug loaded PEO films are presented in Figures 5.13 and 5.14.  The drug 
free PEO film was found to have a tensile strength of 12.8 ± 0.4 MPa and 
its percent elongation was 21.5 ± 3.1 %.  Semi-crystalline polymers 
contain lamellar regions of folded chains which are held together by “tie 
molecules” which extend from one crystalline region to the next [170].  
The crystalline regions are typically denser and harder than the 
amorphous regions.  Chain ends and imperfections tend to occur in the 
amorphous regions between crystalline lamellae where few tie molecules 
exist.  Thus, the tie molecules are the source of strength.  Secondary 
intermolecular forces between polymer chains are also a source of 
strength.  The degree of hydrogen bonding, van der Waals forces and 
dipole-dipole bonds depends upon the packing, flexibility and orientation 
of the polymer chains. 
Semi-crystalline polymers tend to be brittle with little strength.  The 
brittleness is thought to be due to strains imposed on the amorphous 
phase by the crystallites, voids introduced during crystallization or from 
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stress concentrations of crystallites [171].  Fractures generally occur in the 
boundaries between spherulites where few tie molecules exist or along 
the radii of large spherulites [171].  Thus, the mechanical properties of 
semi-crystalline polymers are largely determined by flaws and microscopic 
fractures.   
The influence of guaifenesin and ketoprofen on the mechanical 
properties of hot-melt extruded PEO films is presented in Figures 5.13 & 
5.14.  The percentage elongation of the GFN loaded films was significantly 
less than the drug free film. As the guaifenesin concentration in the film 
increased from 5 to 30%, the elongation decreased from 25.1 to 41.4%, 
respectively, relative to the drug free PEO film.  The tensile strength was 
reduced at all GFN concentrations studied compared to the drug free PEO 
film.  An inverse relationship between tensile strength and guaifenesin 
concentration was observed.  The tensile strength decreased as the 
guaifenesin concentration in the film increased to 15%.  Statistically 
similar tensile strength values were obtained for films containing 15% and 
30% guaifenesin.   
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Figure 5.13:  The percent elongation of hot-melt extruded polyethylene 
oxide (PEO) films and films containing various concentrations of 
guaifenesin (GFN) or ketoprofen (KTP), n= 6. 
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Figure 5.14:  The tensile strength of hot-melt extruded polyethylene 
oxide (PEO) films and films containing various concentrations of 
guaifenesin (GFN) or ketoprofen (KTP), n=6. 
 
 188
In contrast to the guaifenesin containing films, the elongation of 
hot-melt extruded PEO films containing ketoprofen dramatically increased 
as the ketoprofen concentration increased.  The percent elongation of the 
hot-melt extruded film containing 5% ketoprofen was 11% greater than 
the drug free PEO film.  Furthermore, when the ketoprofen concentration 
in the film increased to 10% and 15%, the elongation increased 112% 
and 158% relative to the drug free PEO film, respectively.  This represents 
more than a 2-fold increase in elongation when the ketoprofen 
concentration in the film was increased from 5 to 15%.  Inclusion of 
ketoprofen in the film also reduced the tensile strength compared to the 
PEO film.  Tensile strength decreased in an almost linear fashion as the 
ketoprofen content was increased from 5 to 15%.   
Generally, the addition of a plasticizer increases the flexibility and 
ductility of a film and the elongation increases, but is accompanied by a 
reduction in film tensile strength and modulus of elasticity [14, 157, 172].  
Plasticization therefore results in a soft, tough film.  The mechanism by 
which plasticizers impart flexibility to a film is thought to be due to the 
presence of the plasticizer between polymer chains, which disrupts the 
forces holding the chains together and reduces the number of 
entanglements [66, 173, 174].  Increasing plasticizer concentration 
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enhances this effect.  Thus, it can be concluded that ketoprofen was an 
excellent plasticizer when present at the 15% loading.   
Solid particles have been found to reduce tensile strength, decrease 
elongation at break and increase film stiffness [175-178].  Crystallization 
of GFN in the film causes discontinuities in the polymeric network by 
disrupting hydrogen bonds between polymer segments.  Although the 
GFN-PEO interaction probably occurs by a dipole-dipole interaction (since 
both are polar), this interaction is weaker than the broken hydrogen 
bonds between polymer chains.  The polymer-GFN crystal interface 
constitutes a weak link in the film structure, creating stress.  The stress 
caused by the crystals will increase as their concentration increases, 
reducing the tensile strength.  GFN crystals also reduce the film 
elongation.  Elongation has been considered a measure of the 
deformation capacity of a film.  GFN crystals are flaws in the film which 
enhance the likelihood of rupture and failure, decreasing elongation.   
The differences between the influence of GFN and KTP on the 
mechanical properties of the films can be attributed, in part, to their 
particle shape.  Several researchers [179-181] have proposed that the 
stresses caused by solid particles in a polymeric network are generally 
dependent on the particle shape factor or aspect ratio.  Guth defined the 
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shape factor as the ratio of length of the particle to its diameter [181].  
Pigments with higher values of the shape factor have been found to 
increase the Young’s modulus and the stress concentration in film coatings 
[176, 182-184].  The particle shape of guaifenesin and ketoprofen can be 
observed in the SEM micrographs in Figures 5.15 and 5.16.  Internal 
stress is greater in the rod shaped GFN crystals compared with the plate-
like KTP crystals.   
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Figure 5.15:  SEM micrograph of the surface morphology of guaifenesin 
at 500 x magnification. 
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Figure 5.16:  SEM micrograph of the surface morphology of ketoprofen 
at 5990 x magnification. 
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5.5  CONCLUSIONS 
The results of this study demonstrate that guaifenesin and 
ketoprofen were stable during the extrusion process.  XRD suggested that 
guaifenesin crystallized following the extrusion process, but ketoprofen 
formed a solid solution with PEO.  Melting points corresponding to the 
crystalline drugs were not observed in the films by DSC analysis, 
suggesting that guaifenesin and ketoprofen dissolved in PEO while in the 
molten state.  Crystallization of guaifenesin on the surface of the film 
could be observed using SEM at all concentrations studies, but did not 
reveal ketoprofen crystallization until reaching the 15% level.  Guaifenesin 
and ketoprofen were found to decrease the drive load, increase the 
stability of PEO and plasticize the polymer during extrusion.  The modified 
Hansen solubility parameter correctly predicted miscibility of PEO with 
ketoprofen and immiscibility between PEO and guifenesin.  The percent 
elongation decreased with increasing guaifenesin concentrations, but 
significantly increased with increasing ketoprofen concentrations.  
Guaifenesin reduced the film elongation by disrupting the polymeric 
network.  The elongation of films containing ketoprofen increased due to 
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plasticizing effects.  Both guaifenesin and ketoprofen decreased the 
tensile strength of the film. 
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CHAPTER 6  SUMMARY AND CONCLUSIONS 
6.1  SUMMARY OF RESULTS  
 In this research project, hot-melt extrusion was successfully utilized 
to prepare pharmaceutical dosage forms.  Three different systems were 
prepared:  sustained release polyethylene oxide matrix that controlled the 
release rate of chlorpheniramine maleate by a diffusion and erosion 
mechanism; hydrophobic, diffusion controlled release ethyl cellulose 
tablets; and transdermal and transmucosal films which acted as a drug 
depot.  The physicochemical and mechanical properties and mechanism of 
drug release of the extruded dosage forms were characterized using novel 
techniques.  The influence of processing conditions, properties of the 
polymers, crystalline nature of the drug and polymer ad formulation 
variables were also investigated. 
 
6.2  STABILITY OF POLYETHYLENE OXIDE IN MATRIX TABLETS 
PREPARED BY HOT-MELT EXTRUSION 
The results of this study demonstrated that the thermal stability of 
PEO was dependent on both the storage temperature and the molecular 
weight of the polymer.  Storage of the polymer above its melting point 
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significantly increased its degradation.  Polymer degradation, when stored 
below its melting point, is due to oxygen permeation in the amorphous 
region of the polymer. 
PEO matrix tablets prepared by hot-melt extrusion were sensitive to 
both process temperature and screw speed.  The mechanism of polymer 
degradation during extrusion is both thermal and mechanical.  At very 
high screw speeds, degradation is due to melt fracture.  The amperage 
consumed by the extruder motor drive can be used as an indicator of 
polymer stability.   
The addition of PEO 100K improved processing of PEO 1M and did 
not significantly influence the rate of CPM released from matrix tablets.  
Vitamin E, Vitamin E succinate and Vitamin E TPGS were found to be 
suitable stabilizers for PEO during processing.  Vitamin E succinate and 
Vitamin E TPGS were dispersed at the molecular level in hot-melt extruded 
tablets.  Ascorbic acid was shown to degrade the polymer in solution.  
Drug release rates from hot-melt extruded tablets stabilized with 
antioxidants were dependent on the hydrophilic nature of the antioxidant. 
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6.3  PHYSICOCHEMICAL PROPERTIES AND MECHANISM OF DRUG 
RELEASE FROM ETHYL CELLULOSE MATRIX TABLETS PREPARED 
BY DIRECT COMPRESSION AND HOT-MELT EXTRUSION 
The results of this study demonstrate that the guaifenesin release 
rate was dependent upon the particle size of ethyl cellulose and the 
processing conditions employed to prepare the tablets.  The guaifenesin 
release rate was slower in tablets prepared with the “fine” ethyl cellulose 
particle size fraction due to the presence of fewer soluble drug clusters 
within the matrix.  Tablets prepared by hot-melt extrusion exhibited 
considerably slower drug release relative to those prepared by direct 
compression.  Thermal analysis demonstrated that guaifenesin was 
dispersed in ethyl cellulose at the molecular level in tablets prepared by 
hot-melt extrusion.  The surface morphology of the hot-melt extruded 
tablets was found to depend upon processing temperature.  The 
guaifenesin release rate also decreased with increasing compaction force 
in tablets prepared by direct compression due to greater densification of 
the powder bed.  Analysis of the tablet pore characteristics could be 
correlated to the observed dissolution results.  Drug release in hot-melt 
extruded tablets was found to be in good agreement with the Higuchi 
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Diffusion model.  Tablets prepared by direct compression using “coarse” 
ethyl cellulose were found to release guaifenesin by both diffusion and 
erosion.   
 
6.4  THE INFLUENCE OF GUAIFENESIN AND KETOPROFEN ON THE 
PROPERTIES OF HOT-MELT EXTRUDED POLYETHYLENE OXIDE 
FILMS 
The results of this study demonstrate that guaifenesin and 
ketoprofen were stable during the extrusion process.  XRD suggested that 
guaifenesin crystallized following the extrusion process, but ketoprofen 
formed a solid solution with PEO.  Melting points corresponding to the 
crystalline drugs were not observed in the films by DSC analysis, 
suggesting that guaifenesin and ketoprofen dissolved in PEO while in the 
molten state.  Crystallization of guaifenesin on the surface of the film 
could be observed using SEM at all concentrations studies, but did not 
reveal ketoprofen crystallization until reaching the 15% level.  Guaifenesin 
and ketoprofen were found to decrease the drive load, increase the 
stability of PEO and plasticize the polymer during extrusion.  The modified 
Hansen solubility parameter correctly predicted miscibility of PEO with 
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ketoprofen and immiscibility between PEO and guifenesin.  The percent 
elongation decreased with increasing guaifenesin concentrations, but 
significantly increased with increasing ketoprofen concentrations.  
Guaifenesin reduced the film elongation by disrupting the polymeric 
network.  The elongation of films containing ketoprofen increased due to 
plasticizing effects.  Both guaifenesin and ketoprofen decreased the 
tensile strength of the film. 
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